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ABSTRACT  
Malignant pleural mesothelioma is a rare but fatal tumor caused mainly by asbestos exposure. 
There is no standard treatment as mesothelioma is primarily resistant to all treatments including 
chemotherapy. Asbestos-induced oxidative stress is thought to play an essential role in the 
pathogenesis of mesothelioma in the process possibly increasing the expression of the major 
antioxidant defense mechanisms of the cells. Both chemo- and radiotherapy act at least partly by 
provoking reactive oxygen species (ROS) generation suggesting a role for the intracellular 
antioxidants in drug resistance. Other mechanisms associated with drug resistance include the 
plasmamembrane drug transporters, of which several are also redox-regulated.  
 
In the present study, the expression and possible role of the major antioxidant enzymes (AOEs), i.e. 
manganese superoxide dismutase (MnSOD), catalase, and mechanisms closely related to 
glutathione (GSH) metabolism were investigated in the biopsies of malignant mesothelioma and/or 
cell lines in culture. The methods included Northern Blotting, Western Blotting analysis, 
immunohistochemistry and measurement of specific enzyme activities. Cell damage after oxidant 
or cytotoxic drug exposures was analyzed by lactate dehydrogenase release, depletion of high-
energy nucleotides and microculture tetrazolium dye assay. 
 
MnSOD was highly expressed in mesothelioma tumor biopsies in vivo and cell lines in vitro 
compared to non-malignant mesothelial cells. Mesothelioma cell line expressing the highest 
MnSOD (10 fold compared to non-malignant mesothelial cells) levels also had the highest levels of 
GSH, glutathione S-transferase (GST) and catalase, and was the most resistant cell line to oxidants 
and cytotoxic drugs.  
In contrast to mesothelioma cells, lung A549 adenocarcinoma cells, that represent an oxidant and 
drug resistant cell line, contained similar levels of MnSOD as non-malignant mesothelial cells. 
They, however, also contained higher intracellular GSH levels and catalase than mesothelioma 
cells, and also had elevated levels of γ-glutamylcysteine synthetase (γGCS), the rate-limiting 
enzyme in GSH biosynthesis. In contrast to tumor necrosis factor-α (TNFα), cytotoxic drugs failed 
to induce MnSOD mRNA, protein or activity in A549 cells. Endogenous level of MnSOD or its 
induction by TNFα did not explain oxidant resistance of these cells. GST could not explain the 
resistance of adenocarcinoma cells, as the activity of total GST was lower in adenocarcinoma cells 
than in more sensitive mesothelioma cells. 
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The role of GSH and catalase was also investigated by treating the mesothelioma cells and A549 
adenocarcinoma cells with buthionine sulfoximine (BSO), to block glutathione synthesis, and 
aminotriazole (ATZ) to inhibit catalase. Both BSO- and ATZ-treatment enhanced H2O2 toxicity in 
three mesothelioma cell lines, while only the depletion of glutathione increased epirubicin toxicity. 
BSO treatment also significantly potentiated cisplatin-induced cytotoxicity in mesothelioma and 
adenocarcinoma cells.  
Given the obvious importance of GSH in the oxidant and drug resistance of these tumors, 
altogether 34 mesothelioma tumor biopsies were investigated for both subunits of γGCS. The 
catalytic, heavy subunit of γGCS was highly expressed in most of the cases, whereas the regulatory, 
light subunit (γGCSl) expression was weaker. No expression of these proteins could be detected 
from the non-malignant mesothelium. 
The integral membrane drug transporter, P-glycoprotein (P-gp), immunopositivity was found in 61 
%, and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) immunopositivity in 58 % and 33 
% of 36 mesothelioma biopsies. Normal mesothelium did not express these multidrug resistant 
proteins. There was no significant association between tumor proliferation, apoptosis or patient 
survival and expression of the multidrug resistant proteins.  
 
In conclusion, a simultaneous induction of multiple antioxidant enzymes can occur in human 
mesothelioma cells. In addition to the high MnSOD activity, H2O2-scavenging antioxidant 
mechanisms, γGCS, GST and GSH can partly explain the high oxidant and drug resistance of these 
cells in vitro; the role of catalase during heavy oxidant exposure is possible. MnSOD can be 
induced by TNFα, but the induction, however, does not provide any protection against repeated 
oxidant exposures. Many mechanisms contributing to the resistance of mesothelioma remain to be 
investigated, but γGCS may play important role in the primary drug resistance of this tumor in vivo 
in maintaining the intracellular glutathione-level. The multidrug resistance proteins P-gp, MRP1 
and MRP2 are expressed in mesothelioma cells, but are not likely to be responsible for the primary 
drug resistance of this malignancy.  
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ABBREVIATIONS 
ABC      ATP binding cassette superfamily 
AOEs       antioxidant enzymes 
ATZ       aminotriazole 
BSO       buthionine sulfoximine 
CAT      catalase 
CPM      counts per minute 
CuZnSOD      copper-zinc superoxide dismutase 
ECSOD      extracellular superoxide dismutase 
G6PDH     glucose-6-phosphate dehydrogenase 
γGCS      γ-glutamylcysteine synthetase 
GSH       reduced glutathione 
GPx       glutathione peroxidase 
GR       glutathione reductase 
GS      glutathione synthase 
GSSG       oxidized glutathione 
GST       glutathione S-transferase 
γGT      γ-glutamyl transpeptidase 
HPF      high power field 
Kb       kilobase 
Kd       kilodalton 
LDH      lactate dehydrogenase 
LPR      lung resistance protein 
MDR      multidrug resistance 
MnSOD      manganese superoxide dismutase 
MRP      multidrug resistance protein 
MT      metallothionein 
NSCLC     non small cell lung cancer 
NF-κB      nuclear factor -κB 
NO.      nitric oxide 
P-gp      P-glycoprotein  
ROS       reactive oxygen species 
RNS      reactive nitrogen species 
SCLC      small cell lung cancer 
SOD       superoxide dismutase 
PCR       polymerase chain reaction 
SV40       simian virus 40 
TGFβ      transforming growth factor-β 
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TNFα       tumor necrosis factor-α 
TRX      thioredoxin 
TRXR      thioredoxin reductase 
TS      thymidylate synthase 
XTT      microculture tetrazolium assay  
VEGF      vascular endothelial growth factor 
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INTRODUCTION 
Mesothelioma is a tumor derived from the serosal lining of the pleural, peritoneal or pericardial 
cavities and is most commonly situated in the pleura. Mesotheliomas are rare tumors, accounting 
for only about 1% of all cancer deaths in the world (Hammar, 1994). Pleural mesothelioma is in 
approximately 85-90% of cases an asbestos-initiated lethal malignancy (Mossman et al., 1990). The 
latency period is about 20 to 40 years. Accordingly, the peak in mesothelioma cases is expected in 
2010, although the asbestos usage in most industrialized countries has been abolished from the 
1980’s. The prognosis of mesothelioma is poor, as it is highly invasive and primarily resistant to all 
treatments including radiotherapy and cytotoxic drugs. A major factor in the pathogenesis has been 
considered asbestos-induced oxidative stress, which in turn is known to induce several antioxidant 
mechanisms in the cells (Janssen et al., 1993). Mesothelioma provides an important model for 
cancer research of a therapy-resistant malignancy in which antioxidant mechanisms may at least 
partly explain the resistance. 
 
Intracellular antioxidants offer protection not only against reactive oxygen species (ROS) but may 
also modulate the response to different chemotherapeutic drugs that are used in cancer treatment. 
Manganese superoxide dismutase  (MnSOD) that scavenges superoxide radicals has a controversial 
role in cancer biology. It has been suggested to be a cancer suppressor (Oberley & Oberley, 1997) 
but on the other hand it offers protection against oxidative stress and thereby may confer resistance 
against oxidant producing drugs. MnSOD is overexpressed in only some malignant tumors, but its 
importance in drug resistance is unsolved (Cobbs et al., 1996; Janssen et al., 1998; Nishida et al., 
1993).  
Glutathione has in many studies been linked with drug resistance both for its role as an antioxidant 
but also for its function in detoxification reactions (Tew, 1994). In most recent studies, attention 
has been drawn to the enzymes in glutathione biosynthesis and how the cell maintains its 
glutathione level (Rahman & MacNee, 2000). Studies have also been done with other mechanisms 
that utilize intracellular glutathione and transport it extracellularly (Borst et al., 2000; Keppler, 
1999).  
Glutathione S-transferases are a family of detoxification enzymes that are often associated with 
chemoresistance (O'Brien & Tew, 1996; Tew, 1994). However, the activity of these enzymes is 
unknown in mesothelioma even though polymorphism of GSTM1 has been linked to the 
development of this disease (Hirvonen et al., 1996). 
Catalase in addition to glutathione takes part in scavenging excess hydrogen peroxide in the cells. 
Not many studies link it to drug resistance of malignant cells (Sinha & Mimnaugh, 1990), but its 
role should be clarified in oxidant and drug resistance of mesothelioma. 
The classical inducers of multidrug resistance are the drug export pumps in the plasmamembrane 
that have different substrate specificities. P-glycoprotein has been studied most, but the recently 
discovered MRP family offers new avenues for investigators in cancer biology (Borst et al., 2000; 
INTRODUCTION 
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Pastan & Gottesman, 1987). The first members in the MRP family, MRP1 and MRP2, are 
dependent on intracellular glutathione and they transport glutathione-conjugated substrates. In 
mesothelioma, these mechanisms have not been thoroughly studied before.  
This series of studies was designed to systematically investigate the expression of the most 
important antioxidant pathways and drug transporters in mesothelioma cells in vitro and tumor 
biopsies in vivo. Besides investigating the expression of these mechanisms, their role in oxidant and 
chemotherapeutic drug resistance was assessed in vitro. The expression of the AOEs and related 
proteins was also correlated with tumor growth and patient survival. 
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REVIEW OF THE LITERATURE 
Malignant pleural mesothelioma 
History 
In 1767 J. Lieutaud recognized two pleural tumors in a series of autopsies, but Wagner was the first 
to describe the pathology of a primary malignant pleural tumor in 1870 (reviewed by Browne, 
1995). The term mesothelioma was first used by Eastwood and Martin in 1921(Boutin et al., 1998). 
In 1960 Wagner (Wagner et al., 1960) reported 33 cases of diffuse pleural mesothelioma in South 
Africa, in an area of crocidolite mining. Of these 33 patients, 32 had a history of asbestos exposure, 
and this connected mesothelioma with asbestos. The first reports of mesothelioma in Finland are 
from the 1960’s (Karjalainen et al., 1997).  
 
Epidemiology 
Mesothelioma is a rare disease, but its incidence keeps increasing despite the industrial restriction 
of asbestos usage from 1980’s, as the latency period is approximately 20-40 years. About 70 cases 
of mesothelioma are diagnosed in Finland every year (Mattson et al., 1999). It has been estimated 
that the peak of mesothelioma incidence in Finland will be around 2010, with approximately 100 
cases per year (Karjalainen et al., 1997). The peak incidence has been already achieved in the U.S, 
but e.g. in Britain the number of cases per year is climbing and is expected to increase to more than 
3000 cases per year (Boutin et al., 1998; BTS, 2001). Mesothelioma is more common among men, 
only about 10% occur in women. In about 80-90% of the male cases an obvious asbestos exposure 
is known. In females, it has been suggested that only 23% of mesothelioma cases are asbestos-
related (Attanoos & Gibbs, 1997). Sporadic cases among children and infants occur. 
 
Etiology 
Asbestos is the single most important causative agent of mesothelioma, and the exposure to 
asbestos fibers is usually occupational (Craighead & Mossman, 1982). Other lung diseases are 
caused by asbestos as well, including asbestosis, lung cancer, pleural plaques, pleural fibrosis, 
pleural effusions and pseudotumors (Mattson, 2000). Factors determining the risk of mesothelioma 
include the fiber type, time from exposure, fiber dimensions and fiber surface properties (Jaurand et 
al., 1987; Mossman et al., 1996). There is evidence that persons with a greater intensity and 
duration of asbestos exposure have a higher risk for mesothelioma which, however, can develop 
with minimal exposure. Therefore, the causative role of asbestos is difficult to rule out as most 
adults in the industrialized world have asbestos in their lungs. Fibers greater than 8 µm in diameter 
are most commonly associated with mesothelioma (Attanoos & Gibbs, 1997).  
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Asbestos is a commercial term for a variety of naturally occurring hydrated fibrous silicates 
(Mossman et al., 1996). The material is subdivided into two groups, serpentine fibers and 
amphiboles. The capacity of different types of asbestos fibers to induce mesothelioma seems to be 
greatest with amphiboles like amosite (“brown asbestos”) and crocidolite (“blue asbestos”), 
whereas the serpentine fiber chrysotile (“white asbestos”) is not as tumorigenic (Boutin et al., 
1996).  
Chrysotile comprises 90% of the asbestos used worldwide. In Finland, however, the main asbestos 
used has been anthophyllite, which is one of the amphiboles. It is associated with asbestos-induced 
diseases such as asbestosis and pleural plaques. Mesothelioma cases are rare but some have been 
reported (Karjalainen et al., 1994). Non-asbestos causes of mesothelioma have not been revealed in 
epidemiological studies, but theoretically any agent injuring pleura may cause mesothelioma. These 
include chemical agents, chronic inflammation, viruses and radiation. Smoking does not increase 
the risk for mesothelioma (Rudd, 1995). Recently a possible connection to Simian Virus 40 (SV40) 
was suggested (Carbone et al., 1994). In the late 1950’s and the early 1960’s polio vaccines were 
contaminated with SV40 and millions of people were exposed. In Finland vaccines were not 
contaminated and none of the mesothelioma patients in Finland had received a contaminated 
vaccine. SV40 large T-antigen has been detected in a high proportion of mesothelioma tissue 
specimens. However, other SV40-like DNA sequences were also found in non-malignant pleural 
diseases. The role of SV40 is unclear, event though in the U.S. and many parts of Europe the 
consensus seems to link it to mesothelioma.  
Genetic susceptibility is associated at least with some detoxification enzyme polymorphisms, 
including the homozygous deletion of GSTM1 gene or slow acetylation-associated N-acetyl 
transferase-2 (NAT2) genotype (Hirvonen et al., 1995).  
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Figure 1. Classification of asbestos fibers (modified from Mossman et al., 1996) 
 
 
Pathogenesis and pathology  
The inhaled asbestos fibers must be transported to the pleural cavity to reach the target cells 
(Browne 1995). Parietal pleura is often more extensively involved, but usually it is difficult to 
determine if mesotheliomas begin in the visceral or parietal pleura (Attanoos & Gibbs, 1997). 
When inhaled into the respiratory bronchioles and alveoli, chrysotile fibers are usually fragmented 
by organic acids and cleared by macrophages. Amphiboles are not as easily decomposed and may 
remain unchanged for years/decades. The asbestos fibers are transported to the pleural cavity via 
the lymphatic pathway or by penetrating to the visceral pleura. Amphibole fibers concentrate on 
certain areas of the parietal pleura, called black spots, that are openings of lymph vessels, and at 
these spots the pleura is exposed for years to the effects of asbestos fibers and toxic reactive oxygen 
species (ROS) (Boutin et al., 1996). Free radicals and other toxic oxygen metabolites are 
considered important in the pathogenesis of mesothelioma (Mossman et al., 1989). Fibers 
themselves have redox properties as they contain ferrous iron which catalyses the reaction forming 
ROS (Kamp et al., 1992). ROS are also formed indirectly when phagocytic cells meet the fibers; 
macrophages and neutrophils are known to liberate ROS after asbestos exposure (Klockars & 
Savolainen, 1992; Hedenborg & Klockars, 1987; Nyberg & Klockars, 1990). These active oxygen 
intermediates can participate in the oncogenic process by many different mechanisms. 
Genotoxicity, lipid peroxidation, and oncogene modulation are all possible effects of ROS. The 
long latency period suggests cumulative genetic, cytotoxic and proliferative events (Janssen et al., 
1993). 
 
ASBESTOS 
Serpentine Amphiboles 
CHRYSOTILE 
Mg6Si4O10(OH)8 
CROCIDOLITE 
Na2(Fe3+)2(Fe2+)3Si8O22(OH)2 
 
AMOSITE 
(Fe,Mg)7Si8O22(OH)2 
TREMOLITE 
Ca2Mg5Si8O22(OH)2 
 
ANTHOPHYLLITE 
(Mg,Fe)7Si8O22(OH)2 
ACTINOLITE 
Ca2(Mg,Fe)5Si8O22(OH)2 
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Pleural mesothelioma is divided histologically into three classes (Travis et al., 1999). The epithelial 
subtype comprises about 54% of all mesothelioma cases. Epithelial mesotheliomas may be 
predominantly composed of acinar structures, and differential diagnosis from adenocarcinoma is 
often demanding. Other variants of epithelial mesothelioma also exist. Sarcomatotic 
mesotheliomas, that histologically resemble fibrosarcomas, represent approximately 20% of the 
cases, and the rest of the cases fall into biphasic mesotheliomas, representing about 25% of the 
cases (Hammar, 1994). 
 
Clinical features and diagnosis  
The average age of a patient at the time of diagnosis is approximately 60 years, and there is a strong 
male predominance (Mossman & Gee, 1989). The first symptoms include chest pain, dyspnea, 
weakness and cough. Usually the diagnosis is delayed due to the non-specificity of the symptoms. 
Thoracic radiograph initially shows pleural effusion in 92% of cases, usually on one side. Only in 7 
% a multinodular pleural tumor without fluid is seen (Boutin et al., 1998). In early cases of 
mesothelioma, nodules or plaques of varying size can be detected in the parietal pleura. Serosal 
thickening and consequent effusion is often marked. The majority of cases are unicavitary. 
Mesothelioma seldom sends metastasis, but it is highly invasive, e.g. to the pericardium. 
One of the first diagnostic procedures is cytology of pleural fluid that gives positive results in 
approximately 30% of cases. Another method used for a diagnostic workup is the computed 
tomography (CT) scan. The diagnosis is established by biopsy via thoracoscopy in most of the 
cases. Examination of biopsy of parietal and visceral pleura is the most reliable method for 
diagnosis (BTS, 2001). 
Histological diagnosis is, however, difficult because of structural variability between different 
tumors and even within the same tumor, the main problem being differential diagnosis from 
metastatic adenocarcinoma of the lung. Other differential diagnostic difficulties arise from bening 
mesothelial hyperplasia and sarcomas in cases of sarcomatoid mesothelioma. In addition to the 
typical histopathology, panel of immunohistochemical stains will often suggest the right diagnosis. 
Many antigens stain positively in adenocarcinoma but remain negative in mesothelioma. The 
markers used in the diagnostic procedure include the carcinoembryonic antigen (CEA), 
glycoprotein markers Leu-M1, Ber-EP4 and B72.3, and others like epithelial marker antigen 
(EMA) and human milk fat globulin-2 (HMFG-2). In epitheloid tumors, diastase resistant neutral 
mucin is positive in approximately 70% of adenocarcinomas, but usually negative in epithelial 
mesothelioma. In case of sarcomatoid mesothelioma cytokeratins like CK 5/6 and AE1/AE3 are 
used, as they are generally positive in sarcomas and negative in sarcomatoid mesothelioma. 
Calretinin, that reveals the mesothelial origin, is usually positive in mesothelioma and negative in 
sarcoma and its specificity is over 90% (King & Hasleton, 2001). In differentiating between 
reactive and neoplastic mesothelium attention should be focused on the degree of cellular atypia 
and the presence of collagen necrosis that are highly suggestive of malignancy.  
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Table 1. Immunohistochemistry of pleural lesions (modified from Travis et al., 1999). 
LMW, low molecular weight; HMW, high molecular weight; HMGF, human milk fat globulin; 
CEA, carcinoembryonic antigen; EMA, epithelial membrane antigen; Vim, vimentin. 
-, negative; +/- occasionally positive; -/+, usually negative; +, usually positive. 
 
Treatment and prognosis 
Treatment of malignant mesothelioma remains disappointing, and there is no standard treatment 
(BTS, 2001). As in other malignant tumors, surgery, radiation therapy, chemotherapy, supportive 
therapy or a combination of different modalities are used. No treatment has so far been shown to 
offer better survival than supportive therapy alone. Median survival time from diagnosis is less than 
one year, 5-year survival is less than 5 %. Some factors, however, indicate a more favorable 
prognosis, including epithelial subtype, age < 65 years, good clinical condition with no weight loss, 
and absence of visceral pleura involvement (Hammar, 1994).  
Surgery alone does not improve survival but may be beneficial for palliation. Four different 
surgical methods are in use: extrapleural pneumonectomy, pleurectomy/decortication, limited 
pleurectomy and thoracoscopy with talc pleurodesis. Extrapleural pneumonectomy is often used in 
the combination with radiotherapy. 
Radiotherapy is also used for palliation, especially in cases with pain. Sometimes the disease may 
regress, but significant improvement in survival has not been achieved. Radiotherapy is usually 
given in combination with either surgery or chemotherapy, so the individual effects of the treatment 
modalities are difficult to document. 
 
Diagnostic problem Keratins 
LMW/HMW 
CEA B72.3 Leu-
M1 
BER-
EP4 
EMA 
HMFG-2 
Vim 
Mesothelial hyperplasia 
vs. 
 
+ - - - - -/+ -/+ 
Epithelial 
mesothelioma vs. 
 
+ -/+ -/+ -/+ -/+  + + 
Metastatic carcinoma 
(adeno ca) 
+ + + + + +  -/+ 
Fibrous pleuritis vs. 
 
+ - - - - -/+ + 
Sarcomatoid 
mesothelioma vs. 
 
+ - - - - -/+ + 
Sarcoma (primary or 
metastatic) 
-/+ - - - - - + 
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Many different chemotherapeutic agents have been tested either as single-agent treatment or in 
combination therapy. In the best clinical series, objective responses are seen after single-agent 
therapy in about 20-30% of patients, but no significant effect on the overall survival (BTS, 2001). 
The best results in single-agent treatment have been achieved using anthracyclins, with doxorubicin 
giving up to a 40% response rate and high-dose cisplatin a response rate of up to 33%. Rather 
promising results have been achieved also with carboplatin, epirubicin, ifosfamide and mitomycin. 
High-dose methotrexate treatment resulted in a response rate of 37% in a study of 63 patients 
(Boutin et al., 1998). Combinations of cisplatin, doxorubicin or an alkylating agent like ifosfamide 
have been studied, usually two or three drugs are combined. No clear advantage over single-agent 
therapy has been observed. Combination therapy with cytokines, like interferon-α, has been 
disappointing despite the promising results in in vitro studies (Boutin et al., 1998). The resistance 
mechanisms of mesothelioma tumors have been studied only in few publications and therefore 
remain largely unknown. Some of these studies will be discussed later. 
 
Lung cancer  
Given the difficulties between the differential diagnosis of mesothelioma and lung cancer, this 
study has included experiments also on the biopsies and cell lines of lung cancer, mainly lung 
adenocarcinoma. 
The incidence of lung cancer is increasing due to the habit of tobacco smoking in the world. Over 3 
million lung cancer deaths have been estimated worldwide in the year 2000. In Finland 2 075 new 
lung cancer patients were diagnosed in 1994, after five years only 10% are still alive (Mattson, 
2000). Lung cancer is the second most common cancer among men in Finland. The incidence 
among women is climbing and at present lung cancer is the second most common cause of cancer 
deaths among women. 
Tobacco is the most important etiological agent of all four subtypes of lung cancer responsible for 
approximately 90% of all cases. Other known exogenous risk factors for lung cancer include 
asbestos, ionizing radiation, and other environmental carcinogens e.g. polycyclic aromatic 
hydrocarbons, nitrosamines and aromatic amines. The endogenous, host related factors, include 
immunological factors and genetic predisposition, mainly differences in carcinogen metabolism, 
DNA repair and altered proto-oncogene and/or tumor suppressor gene expression (Vainio & 
Husgafvel-Pursiainen, 1996).   
Lung cancer is divided into two major classes mainly for treatment purposes: small cell lung cancer 
(SCLC) and non small cell lung cancer (NSCLC).  Virtually all cases arise from the epithelial tissue 
and are bronchogenic carcinoma subtypes. SCLC (30% of all lung cancers) proliferates fast, often 
sends metastases and is primarily sensitive to anti-cancer drugs. Therefore, the initial treatment is 
chemotherapy. However, resistance to treatment develops rapidly and many different resistance 
mechanisms have been speculated. P-glycoprotein cannot solely explain the clinical drug resistance 
(Lai et al., 1989) and other possible drug resistance mechanisms include multidrug resistance 
proteins (Wright et al., 1998) and decreased expression of topoisomerase II (Giaccone, 1994).   
NSCLC comprises three histologically different carcinomas: adenocarcinoma (30-35%), squamous 
cell carcinoma (30-35%), and large cell anaplastic carcinoma (5%) (Mattson, 2000). The treatment 
of NSCLC is primarily surgery. Combination chemotherapies are widely used for the treatment of 
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NSCLC since only 10-20% of the cases can be operated. In contrast to SCLC, NSCLC is primarily 
resistant to single chemotherapeutic agents.  In adenocarcinoma, glutathione-related mechanisms 
have been suggested as potential resistance inducers along with other classical resistance 
mechanisms (Giaccone et al., 1996; Oguri et al., 1998a; Oguri et al., 1998b; Scagliotti et al., 1999; 
Sugawara et al., 1995; Zhang et al., 1998). 
 
 
Reactive oxygen and nitrogen species 
A free radical is defined as a chemical species that has a single unpaired electron in the outer orbital 
(Fridovich, 1978). In this state the radical is extremely reactive and unstable. The most important 
radicals are the superoxide radical (O2-.), the hydroxyl radical (OH.), nitric oxide (NO.) and  
peroxynitrite (ONOO-). Reactive oxygen species (ROS) include free radicals and other oxygen-
related reactive compounds, such as hydrogen peroxide (H2O2) (Halliwell, 1991). ROS are 
generated in normal aerobic metabolism in mitochondria, which are the main site of production of 
radicals. In the cytosol and plasma membrane, ROS are formed by NADPH oxidase, cytochrome 
P450 oxidase and xanthine oxidase (see Figure 3). Transitional metals, such as iron and copper, are 
potential promoters of free radical damage, as they can convert superoxide, which in normal 
conditions is poorly reactive, into a rapidly reactive and highly toxic hydroxyl radical by Fenton 
chemistry (Halliwell & Gutteridge, 1985). In Haber-Weiss reaction, hydroxyl radical is generated 
from O2-. and H2O2. NO. has many useful physiological functions, but in excess amounts is a toxic 
free radical as well. Many exogenous agents, such as hyperoxia, radiation, asbestos fibers and 
ozone induce free radical formation in the cell. Asbestos fibers cause oxidant production directly 
and indirectly, one of the ways being catalysis by the ferrous ion, as asbestos fibers have a high iron 
content. Inflammatory cells, such as neutrophils and alveolar macrophages, also produce large 
amounts of ROS when activated, especially when the phagocytosis is incomplete (Kamp et al., 
1992). NO. production is also activated via the induction of inducible nitric oxide synthase by 
TNFα and other cytokines released from the inflammatory cells. Reactive nitrogen species that are 
formed in reactions of NO. and oxygen/superoxide mediate the harmful effects of NO. (Ohshima & 
Bartsch, 1994).  
The pathological effects of ROS are wide-ranging; these toxic products can cause injury practically 
to all cellular components. Lipid peroxidation of membranes, non-peroxidative mitochondrial 
damage, lesions in DNA, and cross-linking of proteins are the most relevant reactions of ROS 
leading to cell injury. ROS are thought to be especially important in lung tissue that is exposed to 
much higher concentrations of oxygen than most other tissues, but also to cigarette smoke and 
environmental pollutants. In addition to the toxic effects, ROS are important in non-toxic cellular 
reactions, including signal transduction (Thannickal & Fanburg, 2000). 
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Figure 2. The pathway of oxygen reduction and peroxynitrite formation 
 
Antioxidants 
To protect themselves from the harmful effects of oxidants, cells have several antioxidant enzymes 
and other antioxidant mechanisms. The latter include glutathione (GSH) and numerous GSH-
dependent enzymes, metal binding proteins, and vitamins. The three main types of antioxidant 
enzymes are the superoxide dismutases (SODs), catalase (CAT) and peroxidases, of which 
glutathione peroxidases (GPx) are thought to be the most important (Halliwell and Gutteridge 
1989). The SODs dismutate the superoxide radical into H2O2. GPx and CAT reduce H2O2 into 
water and oxygen. Glutathione redox cycle provides the cell with reduced glutathione (GSH) to act 
as cosubstrate for the peroxidases but to also participate in detoxification reactions and react non-
enzymatically with OH. and peroxynitrite. Other enzymes involved in glutathione metabolism are 
glutathione reductase, glucose-6-phosphate dehydrogenase, glutathione S-transferases and the 
enzymes participating in GSH-synthesis: γ-glutamylcysteine synthetase (γGCS) and glutathione 
synthase (GS). Metal-binding proteins ferritin, ceruloplasmin, transferrin, haptoglobin and albumin 
contribute to the antioxidant system by inactivating catalytic metals. The most important 
antioxidant vitamins include α-tocopherol, ascorbate, B-carotene and flavonoids, but they will not 
be discussed in this review.  
Other enzymes with antioxidant capacity include cysteine-containing proteins such as the families 
of thioredoxin, glutaredoxin and peroxiredoxin. These may play a role in the resistance of cells 
against oxidants but also against free radical generating drugs (Holmgren, 2000; Powis et al., 2000; 
Rhee et al., 1999).  
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Figure 3. The central intracellular antioxidant mechanisms in mammalian cells. XAO = xanthine 
oxidase, NADPH-ox = NADPH-oxidase, ETC= mitochondrial electron transport chain, TRX = 
thioredoxin, GRX = glutaredoxin, PRX = peroxiredoxin, SOD = superoxide dismutase, CAT = 
catalase, GPx = glutathione peroxidase, GR = glutathione reductase, GSH = glutathione, GSSG = 
oxidized glutathione, GST = glutathione S-transferase, γGCS = γ-glutamylcysteine synthetase, GS 
= glutathione synthase, γGT = γ-glutamyl traspeptidase, G6PDH = glucose- 6-phosphate 
dehydrogenase 
 
Superoxide dismutases 
Two main forms of SOD exist intracellularly: a copper-zinc containing superoxide dismutase 
(CuZnSOD) and a manganese-containing superoxide dismutase (MnSOD) (Fridovich, 1995). 
CuZnSOD is found in the cytoplasm, and MnSOD in the mitochondria. Extracellular SOD 
(ECSOD) is located in the extracellular matrix. 
 
MnSOD (also known as SOD2) is a homotetramer with a molecular weight of 88 000 and is located 
in the mitochondrial matrix close to the electron transport chain, where ROS are produced in 
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normal cellular metabolism (Fridovich, 1998). The gene is located in the long arm of chromosome 
6 and is transcribed as two distinct mRNAs of 1 kb and 4 kb (Church et al., 1992). MnSOD is 
synthesized in the cytoplasm as a precursor molecule containing a leader signal, which is removed 
during the transport of the molecule to the mitochondria (Wan et al., 1994; Weisiger & Fridovich, 
1973). Two polymorphic variants of MnSOD have been described, one leading to altered 
mitochondrial targeting of the enzyme and the other possibly to changed MnSOD in vitro activity 
(Ho & Crapo, 1988; Rosenblum et al., 1996). The importance of MnSOD for normal physiology 
has been proven with knockout mice lacking the MnSOD gene, who died within 10-20 days of 
neurological manifestations and cardiotoxicity (Li et al., 1995). Heterozygous mice with half of the 
MnSOD activity have increased age-related mitochondrial oxidative damage (Williams et al., 
1998). Approximately 15% of total intracellular SOD activity is due to MnSOD.  
In eukaryotic cells, the MnSOD gene regulation is complex. The MnSOD promoter contains 
binding sites for several transcription factors such as AP1, AP2, SP1 and NF-κB. It has been 
hypothesized that the oxidative state of the cell is essential in regulating MnSOD expression. 
MnSOD is induced by the cytokine tumor necrosis factor α (TNFα) (Wong & Goeddel, 1988). 
TNFα binds to its plasma membrane receptor, which initiates a series of events including 
intracellular ROS production, activation of NF-κB and induction of the MnSOD gene. The TNFα 
induction of MnSOD is blocked by the antioxidant N-acetyl cysteine (NAC). Other factors that 
induce MnSOD are hyperoxia, irradiation, oxidized LDL, interleukin-1, interferon-γ, 
lipopolysaccarides, H2O2 and asbestos fibers (Crapo & Tierney, 1974; Harris et al., 1991; Oberley 
et al., 1987; Visner et al., 1990; Warner et al., 1996; Wong & Goeddel, 1988). In some studies the 
MnSOD gene induction is associated with resistance to hyperoxia, which would indicate that 
oxidant stress induces the enzyme to protect from subsequent oxidant injury (Liochev & Fridovich, 
1997; Tsan et al., 1990; Wispe et al., 1992). However, in contrast to many in vivo hyperoxic 
models, MnSOD is not directly upregulated by high oxygen tension in human bronchial epithelial 
cells in vitro (Pietarinen-Runtti et al., 1998). In human lung MnSOD is found in type II 
pneumocytes, bronchial epithelial cells and alveolar macrophages (Coursin et al., 1996; Kinnula et 
al., 1994; Lakari et al., 1998). High levels of MnSOD are also found from the heart, brain, liver and 
kidneys (Beyer et al., 1991). 
In human malignancies, the role of MnSOD is controversial. In carcinogenesis, the antioxidant –
oxidant imbalance is considered significant. A polymorphism of the MnSOD gene resulting in 
alteration in the transport of MnSOD into the mitochondria due to conformational change in the 
protein is a risk factor at least for the development of breast and lung cancers (Wang et al., 2001); 
Ambrosone et al., 1999). Most studies have shown that MnSOD activity is low in cancer cells, and 
it has been proposed to be a cancer suppressor gene (Oberley & Oberley, 1997). Transfection 
studies, in which only the MnSOD gene has been introduced, have shown decreased level of 
malignancy and transformation of the malignant phenotype to the direction of a non-malignant one. 
However, interpretation of this study is problematic as transfection creates imbalanced conditions 
in the cell. On the other hand, at least gliomas, thyroid carcinomas, esophageal carcinomas and 
colon carcinomas appear to contain high MnSOD levels when compared to the non-malignant 
tissues. In a study of five samples of lung tumors the activity of total SOD was somewhat lower 
than in normal lung tissue (Jaruga et al., 1994). In mesothelioma, MnSOD has not been previously 
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studied before our group reported elevated activity of MnSOD in mesothelioma cell lines (Kinnula 
et al., 1996). 
It has been reported that MnSOD is not inducible in cancer cells as it is in non-malignant cells 
(Wong & Goeddel, 1988) but also this issue is controversial. At least human lung adenocarcinoma 
cells show MnSOD induction by TNFα (Warner et al., 1996). Human A549 lung cells also 
represent a malignant cell type but appear to show MnSOD induction (Das & White, 1997).  
 
CuZnSOD (SOD1) is a homodimer with a molecular weight of 32000 and is localized mainly in the 
cytosol, but it is also found in the nucleus and peroxisomes (Crapo et al., 1992; Fridovich, 1998). 
The gene is located in chomosome 21, the gene is transcribed as two mRNAs, 0.9 and 0.7 kb, 
respectively, the latter being the predominant form (Sherman et al., 1984). In contrast to MnSOD, 
CuZnSOD-deficient animals and cells are viable but they are sensitive to oxygen toxicity (Huang et 
al., 1999). Mutation of this gene is associated with familial amyotrophic lateral sclerosis (Rosen et 
al., 1993). 
The regulation of CuZnSOD also differs from MnSOD, e.g. its level is constitutive in several 
animal studies (Clerch & Massaro, 1993) and human lung (Lakari et al., 1998), neither is it induced 
by hyperoxia (Pietarinen-Runtti et al., 1998; Visner et al., 1990), TNFα or interleukin-6 (reviewed 
by Kinnula et al., 1995). In healthy human lung, CuZnSOD is found from the bronchial epithelium 
(Coursin et al., 1996; Lakari et al., 1998). High levels are also found from the liver, erythrocytes, 
brain and neurons. In a recent study CuZnSOD gene was found to be upregulated in a 
mesothelioma cell line compared to a non-malignant mesothelial cell line, when assessed in 
microarray containing over 6900 genes (Rihn et al., 2000). Otherwise its expression and role in 
human tumors remain unclear.  
 
ECSOD is a copper and zinc containing homotetrameric glycoprotein. It is located in the 
extracellular matrix in all human tissues and its gene is located in chromosome 4 (Fridovich, 1998; 
Hendrickson et al., 1990). ECSOD is induced by cytokines like TNFα (Stralin & Marklund, 2000), 
direct oxidant stress does not affect ECSOD like it does MnSOD. In healthy lung, ECSOD is 
concentrated in pulmonary vessels and airways, and also found from systemic arteries (Oury et al., 
1994). Of the pulmonary cell types, it is found from bronchial epithelium, alveolar macrophages 
and endothelial cells (Oury et al., 1994). Its role and regulation in cancer are unknown.  
 
Glutathione  
Glutathione (L-γ-glutamyl- L- cysteinylglycine, GSH) is the predominant intracellular low 
molecular weight thiol in all mammalian cells (Meister, 1983), usually present in the millimolar 
range; the intracellular level being approximately 1-8 mM and the extracellular level typically 5-50 
µM (Griffith, 1999).  About 99% of the intracellular glutathione is in the reduced form. 
Approximately 85% of the intracellular glutathione is in the cytosol, about 15% in the mitochondria 
and a small percentage in the endoplasmic reticulum. The mitochondrial GSH pool is maintained 
by the activity of a mitochondrial transporter that translocates cytosolic GSH into mitochondria 
(Rahman & MacNee, 2000).  
GSH is a central protective antioxidant against free radicals and other oxidants, but it has also an 
essential role in detoxification reactions. Other cellular events where glutathione is considered 
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valuable are modulation of redox-regulated signal transduction, regulation of cell proliferation, 
remodeling of extracellular matrix, apoptosis, mitochondrial respiration and a reservoir of cysteine 
(Rahman & MacNee, 2000). Numerous studies show that resistant human cancer cell lines contain 
high glutathione levels in vitro and that oxidant induced toxicity can be enhanced by buthionine 
sulfoximine (BSO) that causes glutathione depletion by inhibiting its synthesis (Tew, 1994; Zhang 
et al., 1998; Griffith, 1999; O'Brien & Tew, 1996; Sinha & Mimnaugh, 1990). The role of 
glutathione in oxidant and drug resistance has not been previously investigated in mesothelioma. 
 
Enzymes in the glutathione redox cycle: Glutathione peroxidase (GPx) and glutathione 
reductase (GR) 
GPx is one of the major enzyme families in removing hydrogen peroxide generated by, e.g., 
superoxide dismutases. It catalyzes the reaction where GSH is oxidized into GSSG and H2O2 
converted into water and oxygen. Four distinct selenoproteins are included in the family of 
glutathione peroxidases, the classical form being the cytosolic GPx, which is also found in the 
mitochondria and extracellular matrix. The other three are the gastrointestinal form of GPx (Chu et 
al., 1993), a non-selenium dependent GPx (Shichi & Demar, 1990) and phospholipid 
hydroperoxide GPx (Schuckelt et al., 1991).  
The cytosolic GPx, a tetrameric selenoprotein, has a molecular weight of 85 000. The gene is 
located in chromosome 3 (Moscow et al., 1994). Recently a polymorphism was found that 
associated to lung cancer (Ratnasinghe et al., 2000). In normal physiological conditions with low or 
moderate production of H2O2, GPx has been considered a more important scavenger than catalase, 
because its Michaelis-Menten constant (Km value) for H2O2 is lower than that of catalase. 
Selenium is needed in the synthesis of GPx and at least the extracellular GPx is induced by 
hyperoxia and oxidants (Avissar et al., 1989; Erzurum et al., 1993).  
GPx is ubiquitously expressed in erythrocytes, kidney and liver. The expression of GPx in 
malignant tumors is somewhat variable. GPx activity has been suggested to be elevated in 
adenocarcinoma of the lung (Carmichael et al., 1988; Di Ilio et al., 1987) whereas it was decreased 
in other lung cancer subtype biopsies when assessed by immunohistochemistry (Coursin et al., 
1996; Jaruga et al., 1994). Elevated GPx activity has been linked with chemoresistance of anti-
cancer drugs, such as adriamycin, that kills cells by releasing free radicals (reviewed by Sinha & 
Mimnaugh, 1990). 
Glutathione reductase (GR) converts GSSG back to GSH at the expense of NADPH forming a 
redox cycle (see Figure 4). Two isoenzymes of GR, one cytosolic and one mitochondrial, are 
encoded by a single gene located in chromosome 8.  It has been postulated that the glutathione 
conjugates formed in xenobiotic detoxification can inhibit GR thereby accumulating GSSG altering 
the redox capacity of the cell. The expression of GR in human lung and tumors is unclear. 
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Figure 4. The glutathione redox cycle. G6PDH = glucose-6-phosphate dehydrogenase, GR = 
glutathione reductase, GSSG = oxidized glutathione, GPx = glutathione peroxidase and GSH = 
glutathione. 
 
 
Enzymes in glutathione biosynthesis 
γ-glutamylcysteine synthetase (γGCS) is the rate-limiting enzyme in GSH biosynthesis (Richman & 
Meister, 1975). The synthesis requires another ATP-dependent enzyme, glutathione synthase and 
the amino acids glutamic acid, cysteine and glycine. In general, the activity of γGCS defines the 
rate of glutathione synthesis and γGCS is feedback-inhibited by the product, GSH. Cysteine is the 
rate-limiting substrate. Levels of GSH and cysteine are the two factors that regulate the synthesis of 
glutathione under physiological conditions. The importance of glutathione synthesis was proven in 
a recent study which showed that homozygous knockout mouse lacking the γGCS heavy subunit 
gene dies before birth (Dalton et al., 2000). 
γGCS is a cytosolic heterodimer consisting of a heavy subunit (γGCSh, MW~ 73 000) and a light 
subunit (γGCSl, MW ~30 000) (Seelig et al., 1984). γGCSh gene is located in chromosome 6 
(6p12) and γGCSl gene in chromosome 1 (1p21) and two mRNA transcripts are consistently seen 
for both subunits (Gipp et al., 1995). γGCSh is the catalytically active subunit; it also binds the 
feedback inhibitor GSH. It has been suggested that γGCSh alone comprises about half of the 
enzyme activity when compared with the holoenzyme (Mulcahy et al., 1995). Some studies, 
however, have concluded that it has no catalytic activity without the light subunit (Lu et al., 1999). 
γGCSl serves an important regulatory role and reduces the inhibitory effect of GSH. It has been 
suggested that during GSH depletion, in oxidizing conditions, the enzyme undergoes 
conformational changes between subunits that allows an increase in the enzyme activity. In normal 
physiological conditions when abundant amounts of GSH are present, both subunits are needed for 
the enzyme activity (Huang et al., 1993). 
γGCS is induced by several agents, including oxidants e.g. H2O2 and menadione, cytokines e.g. 
TNFα, heavy metals e.g. cadmium and iron, and some chemotherapeutic agents e.g. cisplatin (Lu, 
1999). At transcriptional level γGCS subunits are regulated by a number of regulatory signals, 
including ARE, TRE, AP1 and NF-κB. γGCS activity is also regulated at the post-transcriptional 
and translational level, and phosphorylation/dephosphorylation may control its activity. Possible 
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inhibitors include glucocorticoids, insulin, prostaglandin E (Rahman & MacNee, 2000), and TGF-β 
(Arsalane et al., 1997). Exposure to sublethal doses of oxidants may initiate an adaptive antioxidant 
response, where the intracellular GSH is first depleted leading to oxidant stress and consequent 
γGCS upregulation.  The role of γ-glutamyl transpeptidase (γGT) in regulating γGCS activity 
indirectly by cleaving extracellular GSH has also been suggested (Hanigan, 1998). The expression 
of γGCS mRNA varies between different tissues. In healthy human lung, γGCS mRNA has been 
detected from bronchial epithelial cells (Rahman et al., 1999). 
There are no previous studies on the expression or distribution of γGCS in malignant tumors. It has 
been suggested that as chromosome 1 (loss of 1p21-22) is often deleted in malignant mesothelioma, 
this would predispose an individual to the development of the tumor (Rozet et al., 1998). Elevated 
levels of γGCS have been detected in many drug-resistant malignant cell lines. Chemoresistance 
may be associated with accumulation of GSH, which functions as an antioxidant but is also used in 
detoxification reactions. Glutathione has also been shown to inhibit apoptosis by changing the 
redox state of the cell (Manna et al., 1998). Apoptosis resistance in turn has been considered 
important in the drug resistance of malignant cells. 
 
Glutathione synthase (GS) is a cytosolic homodimer that catalyses the reaction of L-γ-glutamyl-L-
cysteine and glycine that forms GSH. GS is composed of two apparently identical subunits (each 
MV~52 000) and the gene is located in chromosome 20 (Webb et al., 1995). Two forms of 
glutathione synthetase deficiency have been described. One form is mild, causing hemolytic 
anemia, but the other more severe form causes 5-oxo-prolinuria with secondary neurological 
involvement (Webb et al., 1995). The regulation of GS is poorly known.  
In glutathione biosynthesis, the availability of cysteine is crucial. Cysteine is transported into the 
cell by a sodium-dependent A system and cystine, an oxidized form of cysteine, by an inducible 
transporter Xc- (Bannai, 1984). Cystine is then reduced to cysteine that can be used in GSH 
biosynthesis. The transport of cystine is induced by oxidants, such as hyperoxia and H2O2, 
contributing to increased GSH levels during oxidative stress (Deneke & Fanburg, 1989). There are 
no studies on the expression of GS or cysteine transporters in malignant tumors. 
 
γ-glutamyl transpeptidase (γGT) acts as a salvage enzyme in GSH synthesis. The molecular weight 
is 50 kD for the heavy and 25 kD for the light subunit (Arai et al., 1995). The gene is located in 
chromosome 22 (Figlewicz et al., 1993). γGT is located on the plasmamembrane, where it cleaves 
the γ-glutamyl bond in extracellular γ-glutamyl cysteinyl-glycine (Hanigan & Ricketts, 1993). The 
amino acids are returned into the cell and reused for GSH synthesis. γGT is induced by menadione 
and t-butyl hydroquinone (Liu et al., 1998), suggesting its role in protecting cells during oxidative 
stress. In addition to other luminal surfaces of the body, lung epithelium contains high levels of this 
enzyme (Ingbar et al., 1995). There is one study showing that mesothelioma biopsies are negative 
for this enzyme when assessed by immunohistochemistry (Hanigan et al., 1999). In the same study, 
strong immunoreactivity is detected from renal cell carcinoma, adenocarcinoma of the prostate and 
papillary carcinoma of the thyroidea (Hanigan et al., 1999). 
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Glutathione S-transferases (GSTs)  
GSTs are a superfamily of detoxifying enzymes that have broad substrate specifities (Hayes & 
Pulford, 1995). Five families of cytosolic GSTs have been identified in human, of which four have 
been thoroughly characterized: Alpha (α), Mu (µ), Pi (π) and Theta (τ). The genes for GST-µ class 
are all located in chromosome 1, whereas GST-π gene is in chromosome 11. A polymorphism of 
GSTM1 (µ-class) resulting in dysfunction of the enzyme has proven to be a risk factor for 
malignant diseases, including mesothelioma (Hirvonen et al., 1996). The GSTs conjugate GSH 
with compounds containing an electrophilic center and thereby provide critical protection against 
xenobiotics and products of oxidative stress. Since the GSH-conjugate is transported out of the cell, 
intracellular GSH is consumed irreversibly in the conjugation and thus maintenance of intracellular 
GSH levels is essential for the optimal function of GSTs. Many GST enzymes possess GPx activity 
as well. Many of the substrates of GSTs also induce the expression of the GST genes, suggesting an 
adaptive response to chemical stress. Carcinogens and alkylating agents may induce GST-π (Zhang 
et al., 1998). 
The GST-π family is the predominant GST in human solid tumors and has even been used as a 
marker in lung, colon, bladder and other human cancers (Zhang et al., 1998). GST activity is often 
associated with anticancer drug resistance, as the drugs are converted to a less toxic form by the 
conjugation. Based on one study 77% of mesothelioma cell lines expressed GSTπ in 
immunohistochemistry (Dejmek et al., 1998). 
 
Catalase 
Catalase (CAT) is a tetrameric hemoprotein that catalyses the reaction of decomposition of H2O2 
into water and oxygen. It has a molecular weight of 240 000. It is mainly localized in the 
peroxisomes (Davies et al., 1979) but is also found in the cytoplasm and mitochondria in minor 
amounts. The gene is localized in chromosome 11. Patients suffering from acatalasemia have a 
mutation of the CAT gene but are clinically healthy.  Catalase has a higher Km than GPx, which 
suggests a major role for CAT at higher levels of H2O2 but a minor role at physiological levels of 
H2O2 (Halliwell & Gutteridge). Catalase is not abundantly present in the mitochondria, where the 
physiological oxidative stress is at its highest. It has been shown to be induced by high oxygen 
tension in alveolar epithelial cells (Freeman et al., 1986). In other studies, however, no induction 
could be detected in lung epithelial cell after oxidant or cytokine exposures (Erzurum et al., 1993; 
Pietarinen-Runtti et al., 1998).  
There are no systematic studies on catalase in malignant tumors. Some studies have suggested 
variable catalase expression in lung, breast and colon cancers (Cable et al., 1992; Coursin et al., 
1996; el Bouhtoury et al., 1992). One recent study showed that catalase is highly expressed in 
mesothelioma (Kahlos et al., 2001b). No major role has been suggested to catalase in drug 
resistance (Sinha & Mimnaugh, 1990).  
 
Other proteins with antioxidant capacity 
Glutaredoxin and peroxiredoxins are cysteine-containing H2O2-scavenging proteins, that have been 
recently described (Holmgren, 2000; Rhee et al., 1999), but no investigations of these proteins have 
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been conducted in human lung tumors. Thioredoxin is composed of two closely related cysteine-
containing proteins, thioredoxin (TRX) and thioredoxin reductase (TRXR). This group of proteins 
enhances cell proliferation and increases resistance to apoptosis in several in vitro and in vivo 
experimental models (Powis et al., 2000). There are two recent studies showing overexpression of 
TRX and TRXR in lung tumors and mesothelioma (Kahlos et al., 2001a; Soini et al., 2001a). 
However, the expression of these proteins did not correlate with survival in either tumor. 
Heme oxygenase (heat shock protein 32) has also been shown to have antioxidative properties. 
There are no systematic studies on this enzyme in malignant tumors. Based on unpublished studies 
from the Department of Internal Medicine, University of Oulu, it is not overexpressed in 
mesothelioma. 
Metallothioneins (MT) have been proposed as possible inactivators of metal-containing 
chemotherapeutic agents intracellularly. MT’s contain a high level of cysteine and they have the 
ability to bind heavy metal ions. MT content has been found to correlate with the resistance of 
SCLC cell lines to cisplatin (Kasahara et al., 1991). MT is expressed in approximately half of 
mesothelioma tumor biopsies, but does not correlate with patient survival (Isik et al., 2001). 
 
 
ATP-dependent multidrug transporters 
Drug efflux glycoproteins are the most studied mechanisms in primary/acquired cytotoxic drug 
resistance (Bellamy & Dalton, 1994; Kartner et al., 1983; Ling, 1992). These pumps are ATP-
dependent, located in the plasmamembrane, and offer resistance to a wide variety of drugs by 
decreasing their net cellular accumulation. Two separate families are known, namely P-
glycoproteins encoded by the MDR1 gene and the MRP-family of proteins. 
 
P-glycoprotein 
P-glycoprotein is a 170-kDa mammalian ATPase and it belongs to a large superfamily of integral 
membrane transport proteins, called the ATP Binding Cassette (ABC) superfamily (Doige et al., 
1993; Higgins, 1992). It is encoded by the MDR1 gene located in chromosome 7, and two classes 
(classes I and III) of P-gp exist in humans (Childs & Ling, 1994). P-gp is normally expressed in 
detectable quantities at least in colon, adrenal cortex, kidney and liver. The blood-brain barrier has 
a very high expression level of P-gp, which is necessary to restrict the entrance of various drug 
molecules into the central nervous system.  
P-gp is the most studied multidrug resistance mechanism in human cancer. Increased rate of drug 
efflux and in some cases also decreased rate of drug influx result in decreased intracellular drug 
accumulation. It has been suggested that in about 50% of human cancers the MDR1 gene is 
expressed at levels that are thought to be significant (Goldstein, 1995). P-gp is known to transport 
agents such as anthracyclins, vinca-alkaloids, taxol and epipodophylotoxins (Volm, 1998). The 
MDR1 gene has been shown to be regulated by heat shock, arsenite and cadmium as well as other 
cytotoxic compounds (Chaudhary & Roninson, 1993; Chin et al., 1990). Different mechanisms of 
how the pump actually works have been suggested.  P-gp has been mostly studied in hematological 
malignancies because of easy availability of tissue. The general conclusion is that at least in acute 
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myelogenous leukemia, P-gp probably has a role in the development of chemoresistance (Campos 
et al., 1992). 
The significance of P-gp in solid tumors is less clear. In kidney, liver and colon carcinomas the 
expression of P-gp has been associated with shorter survival (Duensing & Slate, 1994; Sinicrope et 
al., 1992; Soini et al., 1996; Verrelle et al., 1991). In adenocarcinoma of the breast the prognostic 
value of P-gp screening remains unclear as controversial results have been obtained (Huang et al., 
1998; Trock et al., 1997; Verrelle et al., 1991). The role of P-gp in other solid tumors, as in urologic 
tumors, may be significant (van Brussel & Mickisch, 1998). However, it has been suggested that it 
may not play role in non-small cell lung carcinoma, as only very low or undetectable levels of the 
MDR1 gene product are expressed in these tumors (Lai et al., 1989). In mesothelioma, one 
immunohistochemical study showed that majority of the cases expressed P-gp (Ramael et al., 
1992). However, its role in mesothelioma remained unclear as in a study of five doxorubicin 
resistant mesothelioma cell lines expression of MDR1 gene could not be detected. (Ogretmen et al., 
1998). 
 
MRP family 
In addition to P-gp, another family of transporter proteins, multidrug resistance proteins, has been 
characterized (Cole et al., 1992). While only two genes encode the P-gps, many more genes seem 
to be related to the MRP family. Currently the family has eight members (Bera et al., 2001; Borst et 
al., 2000). 
 
MRP1 (MW 190 000) was the first member of the family. It shares a 15 % amino acid identity with 
the P-gp and its gene is located in chromosome 16 (Cole et al., 1992). Physiologically, MRP1 
transports leukotriene 4 (Borst et al., 2000). MRP1 knockout mice are viable, but their response to 
an inflammatory stimulus is impaired (Wijnholds et al., 1997).  
Preferred substrates for MRP1 are organic anions and drugs conjugated to glutathione, glucuronate 
or sulfate. MRP1 has proven to be the previously characterized glutathione S-conjugate pump. It 
has been stated that MRP-mediated export of conjugates represents an indispensable terminal step 
in detoxification, and the co-ordinate overexpression with the detoxification enzyme GST leads to 
high level resistance to cytotoxic drugs (Keppler, 1999) (see Figure 4). MRP1 transports vinca 
alkaloids and anthracyclins conjugated to glutathione, and therefore depletion of intracellular 
glutathione results in reversal of the drug resistance (Borst et al., 2000). In many cell lines a 
simultaneous increase in the expression of MRP1 and γGCS is often detected when exposed to pro-
oxidants such as menadione and heavy metals like cadmium and arsenite (Ishikawa et al., 1996; 
Kuo et al., 1998; Kuo et al., 1996). MRP1 has also been linked to the oxidative state of the cell, as 
oxidative stress enhances the expression of MRP1 in cultured cells (Yamane et al., 1998). Cisplatin 
resistance has not been seen in MRP1 overexpressing cells. 
MRP1 is found ubiquitously in the human body; in non-malignant lung tissue MRP1 has been 
detected in bronchial epithelium and hyperplastic pneumocyte II cells; (Wright et al., 1998) 
(Thomas et al., 1994).  
Most histological subtypes of NSCLC, but not SCLC, have detectable levels of MRP, when 
assessed with immunohistochemistry; (Nooter et al., 1998; Sugawara et al., 1995; Wright et al., 
1998). In cancers such as breast cancer (Nooter et al., 1997), gastric cancer (Endo et al., 1996), 
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retinoblastoma (Chan et al., 1997), NSCLC (Young et al., 2001) and neuroblastoma (Norris et al., 
1996) MRP1 expression has been associated with drug resistance or poor patient outcome. In five 
mesothelioma cell lines, MRP1 was found to be overexpressed when compared to non-malignant 
mesothelial cells (Ogretmen et al., 1998). MRP1 tissue expression has not been previously studied 
in mesothelioma.  
 
MRP2 was previously known as the canalicular multispecific organic anion transporter that is in 
normal physiological conditions found in the canalicular membrane of hepatocytes (Borst et al., 
2000; Paulusma et al., 1996).  It has a 45 % amino acid identity with MRP1 and the gene is located 
in chromosome 10 (Borst et al., 2000). Patients with Dubin-Johnson syndrome have inactivating 
mutations in their MRP2 gene and are deficient in their bilirubin–glucuronide secretion (Paulusma 
et al., 1996). In addition to liver, MRP2 is found from kidney and gastrointestines. 
MRP2 in known to handle a similar range of GSH conjugates as MRP1. The expression of MRP2 
in tumor tissues is at present unclear. MRP2 expression in lung cancer cells has not been 
thoroughly studied; in colorectal cancer the mRNA levels of MRP2 correlated with resistance to 
cisplatin (Hinoshita et al., 2000). MRP2 is also expressed in gastric tumor cell lines (Narasaki et al., 
1997). MRP2 mRNA seems to be present in cultured cell lines as well as samples of patient tissues 
with no difference between NSCLC and SCLC (Young et al., 1999). In transfected cells, 
overexpression of MRP2 results in resistance to methotrexate, cisplatin, etoposide, doxorubicin, 
epirubicin and mitoxantrone (Borst et al., 2000; Cui et al., 1999; Konig et al., 1999).  
 
 
 
 
 
REVIEW OF THE LITERATURE 
 
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Model showing the relationship between MRP and glutathione. Some drugs (X) 
conjugated to glutathione by GSTs are then transported by MRP. Others (Y) are cotransported with 
glutathione. In both cases, transport is glutathione dependent and can be blocked with BSO. BSO = 
buthionine sulfoximine, γGCS = γ-glutamylcysteine synthetase, GS = glutathione synthase, GSH = 
glutathione, GST = glutathione S-transferase, GS-X = glutathione conjugate, MRP = multidrug 
resistance protein 
 
Other mechanisms of cytotoxic drug resistance 
Resistance to chemotherapy represents a major source of failure in cancer treatment. Resistance can 
be roughly divided into two classes: primary (intrinsic) resistance, as in mesothelioma and NSCLC, 
and acquired resistance that develops rapidly during treatment, as in SCLC. The mechanisms 
behind these two classes are, however, overlapping. The resistance mechanisms naturally vary 
between drugs that have different mechanisms of action. Most of the information on drug resistance 
has been obtained from anthracyclins and alkylating agents.  Anthracyclins are redox-active 
antibiotic chemotherapeutics and form quinone-hydroquinone structures, when activated. The most 
commonly used anthracyclins are epirubicin, daunorubicin and adriamycin. Menadione and 
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mitomycin C are also quinones that are used in anticancer treatments and form ROS. The use of 
anthracyclins is often limited in clinical practice because of difficult side effect including 
cardiotoxicity. Alkylating agents include cisplatin, carboplatin and ifosfamide. These agents bind to 
DNA interfering with proliferation of the cell. Cisplatin forms intrastand cross-links in DNA, 
especially in-between neighboring guanines. Cisplatin causes renal failure as a side effect due to 
necrosis of tubular cells and is highly emetic.  
The most studied drug-resistance mechanism is, as already mentioned, P-gp. However, other 
mechanisms besides P-gp, MRPs and glutathione conjugation may be involved. Recently, one 
mechanism of interest has been resistance to apoptosis, and the expression of the bcl-2 group of 
proteins such as bcl-2, bcl-XL, mcl-1 and bax are widely investigated. The expression and 
significance of various bcl-2 group proteins are, however, unclear in many cancers, but it is known 
that bcl-2 is associated with decreased and bax with increased apoptosis. Mesothelioma has low or 
undetectable bcl-2 expression and weak to moderate expression of bcl-X, mcl-1 and bax. However, 
the expression levels do not appear to correlate with apoptosis of the tumor or prognosis of this 
disease (Soini et al., 1999). Another oncogene, p53, is associated with enhanced apoptosis and 
widely investigated in malignant tumors (Thompson, 1995). The expression of p53 does not 
correlate with survival of mesothelioma patients, either (Esposito et al., 1997).  
Chemotherapy has been generally agreed to be most successful in rapidly proliferating tumors, and 
therefore many cell cycle proteins have been thought to be involved in drug resistance (Drewinko et 
al., 1981). Topoisomerase II is a ubiquitous nuclear enzyme that is important in DNA functioning, 
replication, recombination and transcription. Decreased activity confers “atypical” resistance to e.g. 
anthracyclins and epipodophyllotoxins in human leukemic cells (Beck et al., 1993). A recent study 
with five mesothelioma cell lines suggested that mutations in topoisomerase IIα can be associated 
with resistance of mesothelioma to etoposide (McLaren et al., 2001). Lung resistance protein 
(LPR), localized in the perinuclear area, is one of four vault proteins which form barrel-like 
structures and its overexpression has been associated with decreased drug response at least in acute 
myeloid leukemia and ovarian carcinoma (Scheffer et al., 1995). In mesothelioma its expression 
has not been studied. 
Thymidylate synthase (TS) plays a central role in DNA biosynthesis and is the target of many 
chemotherapeutic drugs. TS expression has been connected to doxorubicin resistance in lung cancer 
(Volm et al., 1979) but also to resistance to cisplatin (Xu et al., 1991). No studies have been 
conducted on TS expression in mesothelioma. Many solid tumors contain areas of hypoxic cells 
that are more resistant to drugs than the cells in normoxia (Teicher, 1994). This can partly be 
explained by poor vascularisation and hence decreased influx of anti-cancer agents into the hypoxic 
area. However, it has been found that tumors with poor vascularisation can express at least GSTπ, 
TS, MT and P-gp (Koomagi et al., 1995). At present the most rapidly growing area of cancer 
research is undoubtedly angiogenesis of solid tumors (Saaristo et al., 2000). For instance, a recent 
study on mesothelioma reported the expression of several angiogenic cytokines, such as vascular 
endothelial growth factor (VEGF), transforming growth factor (TGFβ) and fibroblast growth factor 
(FGP), in this disease. These cytokines may contribute to the high invasiveness but not to the 
primary drug resistance of mesothelioma (Kumar-Singh et al., 1999). 
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Asbestos fibers provoke oxidative stress, which is thought to play an essential part in the 
pathogenesis of mesothelioma. Mesothelioma is primarily resistant to chemo- and radiotherapy, 
both of which act at least partly by provoking ROS generation in the cells. It can be hypothesized 
that in mesothelioma antioxidant mechanisms may play an important role in the pathogenesis and 
drug resistance and in part explain the poor prognosis. These mechanisms have not been previously 
studied in this disease, neither have the potential mechanisms of primary drug resistance, such as 
the drug export pumps, been explored in mesothelioma. Comparison with lung adenocarcinoma 
gives further information on the specificity of these mechanisms in malignant disease. 
 
The specific aims were: 
 
1. To study the expression and localization of MnSOD in mesothelioma tissue biopsies compared 
to non-malignant mesothelium in vivo and to assess the expression of this enzyme in 
mesothelioma cell lines in vitro. 
 
2. To investigate in vitro the inducibility and role of MnSOD in mesothelioma cells in comparison 
with adenocarcinoma cells with low MnSOD activity. 
 
3. To investigate the activities of catalase and glutathione-associated pathways in mesothelioma 
cells and to evaluate their importance in oxidant and drug resistance. 
 
4. To study γGCS expression in lung and mesothelioma tumor biopsies and cell lines, and to 
assess its significance in primary drug resistance of mesothelioma. 
 
5. To investigate the expression of the multidrug resistance proteins, P-gp, MRP1 and MRP2, in 
mesothelioma tumor biopsies and to evaluate their role in tumor growth and aggressiveness. 
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Table 2. Characteristics of the mesothelioma patients 
Patient AGE/SEX Diagnosis Survival 
(months) 
Asbestos 
exposure 
Smoking 
history 
1 42/F Sarcomatoid 3 nk - 
2 56/M Epithelial 9 + + 
3 57/F Biphasic 21 nk - 
4 58/M Sarcomatoid nk nk nk 
5 63/M Epithelial 1 nk + 
6 74/M Epithelial 124 + - 
7 66/M Epithelial 0 + - 
8 70/F Epithelial 2 - + 
9 70/M Biphasic 14 - - 
10 50/M Epithelial 7 + + 
11 68/M Biphasic 2 nk  
12 63/M Epithelial 9 + + 
13 52/M Sarcomatoid 2 nk + 
14 33/F Sarcomatoid 96 nk - 
15 71/M Sarcomatoid 4 + + 
16 73/M Epithelial 24 nk + 
17 67/M Epithelial 8 - + 
18 59/M Epithelial 8 + + 
19 54/M Epithelial 1 + + 
20 67/M Sarcomatoid 4 - - 
21 78/M Epithelial 21 + + 
22 57/M Biphasic 21 + + 
23 57/M Epithelial 3 nk nk 
24 73/M Sarcomatoid 0 nk + 
25 78/M Epithelial 1 + + 
26 79/M Epithelial 1 + - 
27 63/M Epithelial 5 + + 
28 66/M Epithelial 6 + + 
29 72/M Epithelial 34 + + 
30 73/F Epithelial 40 + nk 
31 68/M Sarcomatoid 5 - - 
32 69/M Epithelial 2 - + 
33 69/M Epithelial 7 + + 
34 77/M Epithelial 11 + - 
35 52/F Epithelial 13 nk nk 
36 67/F Epithelial * - + 
37 62/M Epithelial 13 + + 
38 43/M Epithelial 7 + - 
39 72/M Epithelial 20 + + 
40 44/M Biphasic 5 + + 
41 52/M Biphasic 14 + + 
42 46/M Biphasic 13 + + 
43 54/M Biphasic 6 + - 
nk= not known,  *= still alive 
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MATERIALS  
Mesothelioma patients  
Altogether 43 biopsies of mesotheliomas were included, 7 biopsies were obtained from the Finnish 
Institute of Occupational Health (I) and 36 from the Department of Pathology, Oulu University 
Hospital (V, VI). The clinical data on the mesothelioma patients were obtained from the patient 
records and are presented in Table 2. The survival time was defined as time from diagnosis until 
death. 
 
 
Tissue specimens 
Healthy visceral pleural tissue and mesothelioma specimens were obtained from surgical biopsy, 
lobectomy or pulmonectomy samples. The samples of healthy visceral pleura, verified by light 
microscopic examination, were obtained from individuals who underwent surgery for reasons other 
than malignant mesothelioma or other pleural disease. Histopathologic diagnosis of malignant 
mesothelioma was confirmed, when necessary, in the Mesothelioma Panel of Finland and the 
tumors were classified into epithelial, sarcomatoid or biphasic according to the criteria from WHO 
(Travis et al, 1999). 
 
Cell lines 
Mesothelioma cell lines  
Seven mesothelioma cell lines (M10K, M14K, M24K, M25K, M28K, M33K and M38K) were 
originally established from the tumor tissue of untreated mesothelioma patients, with the exception 
of M10K which was established from a mesothelioma metastasis (Pelin-Enlund et al., 1990). This 
particular patient had received both radio- and chemotherapy prior to surgery. With the exception 
of M25K, all the patients were known to have been exposed to asbestos. The data on these patients 
are presented in Table 3.  The tumor biopsy was processed not more than two hours after surgery. 
The specimen was freshly minced with a scalpel and cultured as described by Pelin-Enlund et al 
(Pelin-Enlund et al., 1990). The continuous cell lines were characterized cytogenetically and the 
tumorigenity of some cell lines was tested on experimental mice. In order to confirm the karyotype 
of the cell lines after culturing up to passage 53, the cells were re-characterized to reveal that no 
major changes had occurred, but the cell lines had remained cytogenetically relatively stable.  
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Table 3. Characteristics of the tumors from which the mesothelioma cell lines originated. 
Based on Pelin et al, 1994 
1
 per gram dry weight 
2
 duration of experiment 52-71 weeks, wit M28K 31 weeks. 
 
Non-malignant transformed mesothelial cell line – MeT5A 
MeT5A is a non-malignant pleural mesothelial cell line from American Type Culture Collection 
(Rockville, MD, USA). The cell line was originally established by transfecting mesothelial cells 
with a plasmid-containing Simian Virus (SV40) DNA. MeT5A cells therefore express the SV40 
large T antigen, but are non-tumorigenic with typical mesothelial morphology (Ke et al., 1989).  
 
Adenocarcinoma cell line - A549 
A549 cells, which are human lung adenocarcinoma cells, were obtained from American Type 
Culture Collection (Rockville, MD, USA). The cell line was initially established from human 
alveolar cell carcinoma, and since it has many pneumocyte II characters (Lieber et al., 1976), it has 
been used both as a model for adenocarcinoma (Das & White, 1997) and type II pneumocyte 
(Rahman et al., 1999).    
 
Cell culture conditions 
The mesothelioma cells and Met5A cells were cultured in monolayer in RPMI 1640 medium with 
10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 
0.03% L-glutamine at 37 C° in 5% CO2 atmosphere. A549 cells were grown in monolayer in F12 
nutrient mixture supplemented with 15% FCS. 
 
Antibodies  
The antibodies that were used in immunohistochemistry and Western blots are listed in Table 4. 
 
 
 
 
Cell line Histological 
subtype 
Fiber content in 
lung1 
Number of 
chromosomes 
Tumor incidence 
in nude mice2 
M10K biphasic 13.0 x 106 38-46 2/5 
M14K epithelial 26.0 x 106 41-45 2/5 
M24K biphasic 11.0 x 106 no data no data 
M25K biphasic no data no data no data 
M28K epithelial 150 x 106 no data 0/7 
M33K biphasic 4.0 x 106 no data 2/5 
M38K biphasic 6.2 x 106 no data no data 
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Table 4. The primary and secondary antibodies used in immunohistochemistry (IH) and Western 
blot (WB). Abbreviations: MnSOD = manganese superoxide dismutase, γGCSh = the heavy 
subunit of γ-glutamylcysteine synthetase, γGCSl = the light subunit of γ-glutamylcysteine 
synthetase, P-gp = P-glycoprotein, MRP = multidrug resistance protein, GST-π = glutathione S-
transferase-π 
 
 
 
Antibody Source  Concentration Secondary antibody 
MnSOD Polyclonal, rabbit anti-human 
(Dr.J.D.Crapo) 
1:1000 IH 
1:10 000 WB 
Swine anti-rabbit 1:2000  
Swine anti-rabbit 1:2000 
    
    
γGCSh Polyclonal, rabbit anti-human 1:1000 IH Anti-rabbit (Zymed Kit) 
 (Dr. T.Kavanagh) 1:40 000 WB Donkey anti-rabbit1:50 000 
    
    
γGCSl Polyclonal, rabbit anti-human 1:1000 IH Anti-rabbit (Zymed Kit) 
 (Dr. T.Kavanagh) 1:20 000 WB Donkey anti-rabbit1:50 000 
P-gp Monoclonal, mouse anti-human 
(JSB1, Alexis Biochemicals) 
1:20 IH Anti-mouse (Zymed Kit) 
MRP1 Monoclonal, mouse anti-human 
(MRPm6, Alexis Biochemicals) 
1:50 IH Anti-mouse (Zymed Kit) 
MRP2 Monoclonal, mouse anti-human 
(Alexis Biocemicals) 
1:50 IH Anti-mouse (Zymed Kit) 
Ki-67 Monoclonal, mouse anti-human (Zymed) 1:50 IH Sheep anti-mouse 1:300 
Caspase 3 Polyclonal, rabbit anti-human 1:2000 WB Sheep anti-mouse  
GST-π Polyclonal rabbit anti-human 
(BioPrep) 
1:5000 WB Donkey anti-rabbit 1:30 000 
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METHODS 
Pretreatments, oxidant and cytotoxic drug exposures  
Buthionine sulfoximine (BSO) is a widely used inhibitor of γGCS for the purpose of depleting 
intracellular glutathione (Buckley et al., 1991). The final concentration of BSO varied between 0.2 
mM (MeT5A, M14K) and 1mM (M38K). These concentrations were tested in preliminary studies 
in which cell survival and intracellular GSH concentrations were analyzed. The pretreatment time 
was overnight (16-18h).  
Aminotriazole (ATZ) inactivates cellular catalase (Margoliash et al, 1960) Cells were pretreated 
with 20 (II) or 30 (III) mM ATZ for 60 min. These concentrations were selected on the basis of 
previous studies (Kinnula et al., 1991) and also in the preliminary experiments of this study (II). 
TNFα is a cytotoxic cytokine released from inflammatory cells. It causes NF-kB activation and 
ROS generation in cells and its effects are numerous (reviewed by Vanden Berghe et al., 2000). 
The concentration of TNFα was 10 ng/ml and the exposure time 24-48 h. 
Menadione is a quinone that creates continuous oxidant stress by forming a redox cycle 
intracellularly (Frei et al., 1986). The continuous generation of oxidants is considered to provide a 
better model of physiological/pathological conditions in the cell than a bolus of oxidants. H2O2, on 
the other hand, causes a relatively short oxidant stress and is quickly decomposed intracellularly. 
The concentrations used were 10-100 µM for menadione (4-48h) (I, II, III) or 0.01-1 mM for H2O2 
(1-48h) (II, III). 
The cytotoxic drugs used in these experiments (I, II, III, IV, V) were epirubicin, cisplatin, vindesin 
and methotrexate. Epirubicin, an anthracyclin, is activated to free radical state and, in addition, it 
interacts with molecular oxygen to generate ROS and thus causes oxidant-mediated DNA damage 
(Sinha & Mimnaugh, 1990). Epirubicin was chosen since it is widely used in the treatment of 
mesothelioma. The concentrations varied between 0.005 µg/ml- 0.5 µg/ml (0.01-1 µM). Cisplatin is 
an alkylating agent and has a platinum complex in the cis-position. Glutathione-related mechanisms 
have been linked to resistance against cisplatin (Zhang et al., 1998). In addition to other pulmonary 
malignancies, cisplatin is also used in the treatment of mesothelioma. Cisplatin concentrations 
varied between 0.02-2 µM in (III), 20-250 µM (IV) and 10-100 µM (V). Methotrexate is a 
dihydrofolic acid reductase inhibitor but has been shown to alter also γGCS and GPx activity 
(Kussmann et al., 1993). The concentration varied between 0.01-1 µM (III). Vindesin interferes 
with microtubule formation in the mitotic spindle, and mainly P-gp has been suggested to explain 
resistance against it. The concentration varied between 0.007-1 µM. All exposure times were 48h. 
 
Northern Blot analysis 
The cells were scraped into 4 M guanine thiocyanate buffer and the samples were immediately 
frozen at –70° C. Total RNA was isolated with the acid phenol-chloroform method of 
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Chomczynski and Sacchi (Chomczynski & Sacchi, 1987). Denaturated RNA samples (10-15 µg) 
were electrophoresed on 1% agarose gel with 0.36 M formaldehyde. The RNA was transferred onto 
Hybond-N nylon filters after ethium bromide staining and UV examination to check the loading 
homogeneity, and cross-linked to the filters by UV illumination. The filters were prehybridised at 
58.5° C for more than one hour in a buffer containing 50% deionized formamide, 5 x saline -sodium 
citrate (SSC), 50 mM sodium phosphate at pH 6.5, 5 x Denhardt’s reagent, and 100 µg/ml herring 
sperm DNA. 
The cDNA probes for MnSOD, CuZnSOD, catalase and glutathione peroxidase were kindly 
provided by Dr. Y.-S. Ho from Wayne State University, USA. Filters were hybridized with 32P-
labeled cRNA probes representing human MnSOD (Ho & Crapo, 1988), human CuZnSOD 
(Halliwell & Gutteridge, 1985), human catalase (Quan et al., 1986) or rat GPx (Ho et al., 1988), 
each cloned into the pSP65 vector. The probes were purified by NucTrap columns (Stratagene) and 
added to the prehybridization solution at 2x106 cpm/ml. Hybridization was carried out overnight at 
58.5 °C with shaking. The filters were washed thoroughly and autoradiography was performed at –
80 °C using Kodak BioMax MR film (Eastman Kodak Co, Rochester, NY, USA). After 
autoradiography, the filters were hybridized with a β-actin control probe transcribed from pTRI-β-
actin plasmid (Ambion, Austin, TX, USA). The enzyme mRNA expressions were quantified 
relative to actin expression by an X-rite 331 Transmission densitometer.  
 
Western blot analysis 
The cells were detached with trypsin, centrifuged, and washed with phosphate buffered saline 
(PBS), then mixed with the electrophoresis sample buffer and boiled for 5 min at 95 C°. Cell 
protein was measured by using the Bio-Rad method, and 50 µg (I), 30 µg (II) and 70 µg (V) of cell 
protein were applied per lane in a 12% sodium dodecyl sulphate-polyacrylamide gel.  The gel was 
electrophoresed for 1.5 h (90 V) at room temperature and the protein was transferred (60 min, 
100V) onto Hybond ECL nitro cellulose membranes (Amersham, Buckinghamshire, UK) in a 
Mini-PROTEAN II Cell (Bio-Rad, Hercules, CA). The blotted membrane was incubated with 
rabbit antibodies to MnSOD (dilution 1:10 000), GST-π (dilution 1:5000), γGCSh and γGCSl  
(dilution 1:40 000, 1:20 000) or to caspase 3 (dilution 1:2000), followed by a secondary antibody 
conjugated to horseradish peroxidase (Amersham) (dilution 1:30 000 (I, II); 1:50 000(V, IV)). 
MnSOD, GST-π, γGCS and caspase 3 protein were detected by an enhanced chemiluminescense 
system (ECL, Amersham), and the luminol excitation was imaged on X-ray film (Biomax MR, X-
Omat, USA).  
 
β-actin expression was analyzed in MnSOD, GST-π and γGCS Western blots in order to confirm 
loading homogeneity. The membranes were first stripped of antibodies and reprobed using a 
monoclonal anti-actin antibody and secondary antibody that was conjugated to horseradish 
peroxidase. β-actin was detected and imaged as described above. 
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Enzyme activities 
The activities of the antioxidant enzymes were evaluated in MeT5A, M14K, M38K and A549 cells. 
For the assays the cells were detached with trypsin, pelleted and frozen immediately at –70 °C until 
analysis. The cells were resuspended in PBS and treated with 1% Triton X-100 to disrupt the 
cellular organelles.  
 
MnSOD 
Total superoxide dismutase activity was assessed with some modifications using the method of 
McCord and Fridovitch (McCord & Fridovich, 1969). The activity of the enzyme was measured 
following the decrease in the rate of reduction, in other words the absorbancy change rate at 550 
nm, of 12.8 µM cytochrome c in the presence of 0.5 mM xanthine and xanthine oxidase. MnSOD 
activity was distinguished from CuZnSOD activity by its resistance to 1 mM potassium cyanide. 
The results are expressed as units per mg of total cellular protein.  
 
Glutathione reductase and glutathione peroxidase  
Glutathione peroxidase activity was assessed by measuring NADPH oxidation in the presence of t-
butylhydroperoxide, glutathione reductase and glutathione according to Beutler (Beutler et al., 
1975). Glutathione reductase activity was determined by measuring the oxidation of NADPH in the 
presence of oxidized glutathione GSSG (Beutler et al., 1975). Enzyme activities are expressed as 
units per mg of total cellular protein. 
 
GST  
Glutathione-S-transferase was measured spectrophotometrically using 1mM 1-chloro-2,4-
dinitrobenzene and 1mM glutathione (Habig & Jakoby, 1981). Enzyme activity is expressed as 
U/mg protein. 
 
Catalase 
Catalase activity was assessed according to Kinnula et al (Kinnula et al., 1992). The enzyme 
activity was measured polarographically by following oxygen production with a Clark oxygen 
electrode fitted into a stirred chamber. The cells were sonicated in Tris-EDTA (pH 7.4) and the 
reaction was started by adding the cells into the buffer containing 0.5 mM H2O2 equilibrated with 
nitrogen. The effect of catalase inhibition was tested with ATZ. The activity is expressed as units 
per mg of total cellular protein.  
 
Glutathione content 
Total glutathione content was determined spectrophotometrically following the reduction of 5,5'-
dithiobis (2-nitrobenzoic) acid by NADPH in the presence of glutathione reductase (Beutler et al., 
1975, Akerboom et al., 1981). Glutathione content is expressed as nmol/ mg protein. Proteins were 
analyzed by the micromethod of BioRad (Hercules, Ca, USA). 
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Immunohistochemistry 
The biopsy material was first fixed in 10% neutral formalin, dehydrated and embedded in paraffin. 
Four micron thick sections were cut from a representative paraffin block, the sections were 
deparaffinized in xylene, and rehydrated in through a series of ethanol solutions. Endogenous 
peroxidase was consumed by incubating the sections in hydrogen peroxide in absolute methanol 
(0.3% for 30min, I; 0.1% for 10 minutes IV, V, VI). To enhance the immunoreactivity, the sections 
were incubated in 10 mM citrate buffer (pH 6.0) and boiled in a microwave oven for 2 min at 850 
W and 8 min in 350 W. The paraffin blocks were then incubated with 2% milk powder to diminish 
background staining.  
 
For immunocytochemistry (I), cells (MeT5A, M14K and M38K) were grown on microscopic slides 
(slidechambers, Nalge Nunc) using the same culture conditions as already described. The cells were 
air-dried and heat-fixed at 38°C for 1 h before further processing. 
A modification of immunocytochemistry was applied to evaluate proliferation and apoptosis. In V 
the cell pellets from cell cultures were fixed in 10% neutral formalin overnight, after which 
formalin was removed, and melted 2% agar was laid over the pellets. The agar blocks were further 
embedded in paraffin. Four micron thick sections were cut from the cell blocks and processed 
further as described above. 
 
MnSOD (I) 
The polyclonal rabbit antibody for human MnSOD was a generous gift from Professor James D. 
Crapo (National Jewish Medical Center, Denver, Colorado). After blocking the endogenous 
peroxidase activity, the sections were incubated with the primary antibody overnight at room 
temperature. After incubation with a biotinylated swine anti-rabbit secondary antibody for 30 min, 
the avidin-biotin complex treatment for 30 min was performed. Diaminobenzine was used as a 
chromogen. The sections were lightly counterstained with haematoxylin and mounted with Eukitt. 
PBS or normal rabbit serum were used instead of primary antibody in negative controls. 
 
γ-glutamylcysteine synthetase (IV,V) 
The polyclonal rabbit antibodies for human γGCSh and γGCSl were kindly provided by Dr. 
Terrance Kavanagh (University of Washington, Seattle, Washington, USA). The sections were 
incubated with the primary antibodies for γGCSh and γGCSl, the immunostaining was done using 
the Histostain-Plus Kit (Zymed Laboratories Inc, South San Francisco, CA) and the chromogen was 
aminoethyl carbazole (AEC) (Zymed Laboratories Inc.) In negative controls the primary antibodies 
were substituted with PBS or non-immune rabbit serum. 
 
P-gp, MRP1 and MRP2 (VI) 
A mouse monoclonal IgG1 antibody to human P-gp (JSB1, Alexis Biochemicals), MRP1 (MRPm6, 
Alexis Biochemicals) and MRP2 (Alexis Biochemicals) were used in incubation of the tumor sections. 
The immunostaining was done as with γGCS immunohistochemistry, except that the primary antibody 
was replaced by non-immune mouse or rat serum when assessing negative control stainings. 
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Ki-67 as a marker of proliferative activity (V, VI) 
Tumor cell proliferation was studied with a monoclonal mouse anti-human Ki-67 antibody (Zymed, 
San Francisco, CA, USA). Ki-67 was developed using diaminobenzidine as a chromogen, and the 
sections were lightly counterstained with haemotoxylin and mounted with Eukitt as with MnSOD.  
 
 
Light microscopic evaluation of immunoreactivity (I, IV, V, VI)  
A semi-quantitative assessment of the immunohistochemistry of γGCS, P-gp, MRP1 and MRP2 
was employed by grading the staining as (0) negative, (1) < 33%, (2) 33-66%, (3) 67-100% of 
tumor cells showing positive staining. In MnSOD immunohistochemistry the staining was 
classified into five groups as (0) negative, (1) <25%, (2) 25-50%, (3) 51-75% and (4) >75%. The 
intensity of the immunostaining was graded as (0) negative, (1) weak, (2) moderate, and (3) strong 
(V), with the multidrug resistance proteins also (4), very strong, was used (VI). 
The qualitative and quantitative immunostaining scores were added in order to get a combined score 
for the immunoreactivity. The score was divided into four main groups (V, VI); 
- = no immunostaining; score 0 
+ = weak immunostaining; scores 1-2 
++ =moderate immunostaining, scores 3-4 
+++ =strong immunostaining, scores 5-8 
Two authors did the evaluation of immunostaining separately. In immunocytochemistry, the 
staining of MnSOD was assessed by grading the average staining intensity of the tumor cells in 
comparison with the negative controls and non-malignant mesothelial cells (I).  
The results for Ki-67 immunostaining were also divided into groups as follows.  
Weak staining= less than 5 % of cell nuclei positive 
Moderate staining= 5-10 % of cell nuclei positive 
Strong staining= 10-50 % of cell nuclei positive 
Very strong staining= over 50 % of cell nuclei positive 
 
Assessment of cytotoxicity 
Lactate dehydrogenase release (I, II) 
Lactate dehydrogenase (LDH) release was measured from MeT5A, M14K and M38K cells in order 
to evaluate lytic cell damage. The cells were first exposed to menadione or epirubicin (I) or H2O2 
and epirubicin (II). LDH was measured spectrophotometrically using pyruvic acid as the substrate 
(Bergmayer & Bernt, 1974). Total cellular LDH was measured from cell lysates obtained by 1% 
Triton X-100 treatment. The results are expressed as percent of LDH released into the medium 
from the total LDH amount from the cells and the medium. 
 
Nucleotide depletion (II, V) 
Depletion of high-energy nucleotides was used because of the sensitivity of this method in the 
assessment of cell injury. The cells were incubated for 16 h with 0.1 mM [14C] adenine (specific 
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activity 51-55 mCi mmol –1) to prelabel the high-energy nucleotides in intact cells. After labeling, 
the cells were washed three times and then exposed to menadione, epirubicin (I) or cisplatin (V). 
After the exposure the medium was collected and the cells were extracted with 0.4 M perchloric 
acid. Thin-layer chromatography was used to separate the purine nucleotides (ATP, ADP and 
AMP) both in the cell extract and the medium and the nucleotide catabolic products (xanthine, 
hypoxanthine, uric acid) in the medium. The results are expressed as per cent distribution of 
radioactivity (counts per min, cpm) between nucleotides in the cells, nucleotides leaked to the 
medium and catabolic products in the medium. 
 
XTT-assay (III, IV) 
In selected experiments a cell proliferation kit, the microculture tetrazolium dye calorimetric assay 
(XTT assay) was used to assess cell damage. This method was conducted using a commercial kit 
according to the instructions of the manufacturer (Boehringer, Mannheim, Germany). The cells 
were grown in a 96-well microtiter plate and exposed to cisplatin for 48 hours. After the exposure, 
50 µl of labeling mixture was added to each well and the absorbance was measured with the 
microculture plate reader (Victor; 1420 Wallac Inc, Turku, Finland). Viability of the cells is 
expressed as relative absorbance. 
 
Viability, apoptosis and cell proliferation 
Viable cells were counted under the microscope after pretreatment with TNFα, exposure to 
epirubicin (III) and exposure to various concentrations of cisplatin in cell cultures pretreated with 
BSO (V). Apoptosis was assessed by the ApopTag (Oncor, Gaithesburg, MD, USA) in situ 
detection kit both in tissue biopsies and cultured cells. ApopTag detects the 3'-ends of the DNA 
fragments generated by apoptosis-associated endonucleases. The sections were dewaxed in xylene, 
rehydrated in ethanol and incubated with 20 µg/ml proteinase K at room temperature for 15 min. 
Endogenous peroxidase activity was blocked by 2% H2O2. After this, the slides were exposed to 
terminal transferase enzyme and digoxigenin-labeled nucleotides. The slides were then incubated 
with anti-digoxigenin antibody labeled with peroxidase. The color was developed with 
diaminobenzine-H2O2 and the samples were lightly counterstained with haematoxylin. Cells were 
defined as apoptotic, if the whole nuclear area of the cell labeled positively. Apoptotic bodies were 
defined as small positively labeled globular bodies in the cytoplasm of the tumor cells that could be 
found either singly or in groups. To estimate the apoptotic index (the percentage of apoptotic events 
in a given area), apoptotic cells and bodies were counted in 10 high power fields (HPFs) and this 
figure was divided by the number of tumor cells in the same HPFs.  In addition apoptosis was 
assessed by Western blot analysis where caspase 3 cleavage was detected as already described. 
Caspase 3 is a cysteine protease acting as an executor enzyme in the late phase of apoptosis (Nunez 
et al., 1998). 
Ki-67 was used in the assessment of tumor cell proliferation. The antibody reacts with Ki-67 
nuclear antigen associated with cell proliferation (Table 4). The antigen is present throughout the 
cell cycle except in the resting cells in phase G0. The results for Ki-67 immunostaining were 
evaluated by counting the percentage of positive nuclei out of the total tumor cell population. 
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Statistical analysis 
SPSS (7.5) for Windows was used for the statistical analysis. Comparisons between two 
independent groups were performed using independent samples t-test or Mann-Whitney U-test. 
With dependent groups paired samples t-test was used. Analysis of variance and Kruskal-Wallis 
test or Scheffe’s post hoc test were used when comparing several independent groups. The 
significance of association was determined by Fisher’s exact probability test, correlation analysis 
and two-tailed t-test. The survival analysis was performed by the Kaplan-Meyer curve and the 
survival in relation to the histochemical findings was assessed by the log rank, Breslow tests and 
Tarone-Ware tests. In the immunoreactivity evaluation, correlation coefficient obtained from the 
results of two investigators was established according to Cohen’s kappa statistics (IV, V, VI) 
(Silcocks, 1983). P-value less than 0.05 was considered statistically significant. 
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RESULTS 
Expression of antioxidant enzymes in mesothelioma cells (I) 
In human healthy visceral pleura no MnSOD immunoreactivity could be detected in five of the six 
biopsies (Fig 1a, I). In one case the mesothelial surface of the visceral pleura showed a granular 
layer of immunoreactivity.  
All seven biopsies from mesotheliomas showed moderate or intense immunoreactivity in the 
malignant cells (Fig 1b, 1c, I). The immunoreactivity ranged from moderate to intense within the 
same sample. 
MnSOD was also detected in the mesothelial cell line MeT5A and the mesothelioma cell lines 
M14K and M38K. MeT5A cells, however, showed positive immunoreactivity only in cell clusters, 
whereas M38K cells showed intense staining in all cells. The protein expression of MnSOD was 
verified with Western blot -assay.  
In addition to MnSOD, CuZnSOD, catalase and glutathione peroxidase were assessed in the cell 
lines by Northern blot analysis and specific activity measurement. These results indicated that 
M38K cells had a higher level of these enzymes when compared to MeT5A and M14K cells that 
they were also more resistant to menadione and epirubicin [ Fig 7, Fig 8, (I) Table 1,(II)] 
 
Protection of mesothelioma cells against hydrogen peroxide and epirubicin (II) 
Total GST activity and the levels of GSH were higher in M38K cells than in MeT5A and M14K 
cells (Table 1, II ). M38K cells were also most resistant to hydrogen peroxide, as judged both by 
LDH-release and by depletion of high-energy nucleotides (Fig 1, II). Aminotriazole (ATZ) to 
inactivate catalase and buthionine sulfoximine (BSO) to inhibit γGCS, the rate limiting enzyme in 
GSH synthesis, were used to study the importance of the hydrogen peroxide scavenging 
mechanisms catalase and glutathione redox cycle in oxidant and drug resistance. After ATZ 
pretreatment, the activity of CAT decreased by 85% in MeT5A, 82% in M14K and 89% in M38K 
cells. Pretreatment with 0.2 mM BSO decreased glutathione to undetectable levels in MeT5A and 
M14K cells. In M38K after 0.2 mM BSO pretreatment 15% of baseline glutathione remained, and 
the concentration of 1 mM BSO was chosen for further experiments (7% of baseline GSH left). 
ATZ or BSO alone in these concentrations did not cause nucleotide depletion in any of the cell 
lines and were considered non-toxic. 
Pretreated MeT5A and M14K cells were exposed to 0.1 mM and M38K cells to 0.5 mM H2O2 for 4 
h. In M14K cells only BSO pretreatment potentiated nucleotide depletion, whereas in MeT5A and 
M38K cells both ATZ and BSO pretreatment enhanced adenine nucleotide catabolism in H2O2 
exposed cells (Fig 2, II). 
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Similar experiments were conduced with epirubicin. MeT5A and M14K cells were exposed to 0.1 
µg/ml, and M38K to 0.5 µg/ml epirubicin for 48 h. BSO pretreatment potentiated epirubicin 
toxicity in all three cell lines when assessed by nucleotide depletion, whereas ATZ pretreatment 
had no effect on the cellular nucleotide levels in any of these cell lines (Fig 3, II).     
We also found a higher level of GST-π protein in M38K cells compared to MeT5A and M14K 
cells, suggesting that this isoenzyme may be essential in the drug resistance of these cells (Fig 4, II) 
 
Antioxidant mechanisms in mesothelioma cells in comparison to lung 
adenocarcinoma cells (III) 
The inducibility of MnSOD was investigated in the mesothelioma cell line M14K and in the human 
lung adenocarcinoma cell line A549. A549 cells contained lower basal level of MnSOD than M14K 
cells, the activity being 1.8 + 0.6 and 28.3 + 5.8 U/mg protein, respectively. In A549 cells all the 
cytotoxic drugs tested with the exception of methotrexate caused a modest increase in the mRNA 
level of the 4-kb transcript of MnSOD, but TNF-α a much higher increase in both 1 kb and 4 kb 
transcripts (Fig 3, III). TNFα increased the level of MnSOD protein in both cell types (Fig 1, III), 
but none of the cytotoxic drugs tested (cisplatin, epirubicin, methotrexate or vindesin) had any 
effect. The specific activity of MnSOD was induced significantly by TNFα only in A549 cells 
(+524%) (Fig 2, III) but the cytotoxic drugs had no inducing effect on the specific activity in either 
cell type. 
A549 cells were more resistant against menadione and epirubicin than M14K cells (Fig 4, III). The 
hypothesis that MnSOD induction may increase oxidant and drug resistance was tested in A549 
cells. TNFα pretreated cells were exposed to either menadione (16 h) or epirubicin (48 h) at 
concentrations that caused the loss of approximately 50% of the control cells. MnSOD induction 
did not protect these cells against either of these exposures (Fig 5, III). 
A549 cells were also more resistant against exogenous H2O2 than M14K cells, which suggested the 
importance of the protective role of catalase and/or glutathione. The specific activity of CAT was 
approximately twice as high in A549 cells than M14K cells, and total glutathione levels were 
approximately 2.5 times higher (Fig 7, III). The depletion of CAT (with ATZ) or glutathione (with 
BSO) made A549 cells more vulnerable to oxidant injury caused by H2O2 but only BSO 
pretreatment had an effect on the toxicity caused by epirubicin. The hypothesis that glutathione-
related mechanisms are important for the resistance of A549 cells was supported by Western blot 
studies showing that γGCSh was prominently expressed in A549 but not in M14K cells (Fig 7, III). 
Furthermore, depletion of GSH with BSO enhanced the injury in A549 cells when exposed to 
cisplatin (Fig 1, IV). The activity of total GST was somewhat lower in A549 than in M14K cells, 
suggesting that GST may not be involved in the oxidant resistance of these adenocarcinoma cells.  
 
Expression of γGCS subunits in lung tumor and mesothelioma biopsies (IV, V) 
Antibodies for the heavy and light subunits of γGCS were used in staining lung tumor biopsies and 
cell lines. These antibodies were shown to be applicable in the histochemical assessment of paraffin 
embedded tissues, and γGCSh and γGCSl subunits were expressed in lung malignancies (Fig 1, IV). 
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Both subunits of γGCS were investigated in five samples of non-malignant mesothelium and 34 
mesothelioma tumor biopsies. Non-malignant mesothelium showed no expression of γGCSh or 
γGCSl in any of the samples (Fig 1, V). Most mesotheliomas (29/34) showed strong intensity of 
immunoreactivity for γGCSh. The combined qualitative and quantitative scores of immunostaining 
are shown in Table 1(V).    
The intensity of  γGCSl immunoreactivity was considerably weaker. Of the 34 cases, 12 cases 
showed no immunoreactivity with the light subunit antibody, strong/moderate staining was seen in 
15 cases. The histologic type of mesothelioma had no statistically significant effect on γGCS 
reactivity even though the epithelial subtypes had a tendency to show stronger immunoreactivity. 
There was no correlation between either γGCSh or γGCSl immunoreactivity and patient survival. 
 
Expression and possible role of γGCS in mesothelioma cells in vitro (V) 
Seven mesothelioma cell lines were investigated for the expression of both γGCS subunits with 
Western blot analysis. Both subunits were detectable in all cell lines (Fig 2, V).  The cell line most 
resistant to oxidants, M38K, contained the highest level of γGCSh. 
In the nucleotide depletion assay, M38K cells were more resistant to cisplatin than M14K cells. 
Pretreatment with BSO to deplete intracellular glutathione potentiated the cisplatin-induced toxicity 
significantly (Fig 4, V).  
Caspase 3 cleavage was used as an indicator of the apoptotic process. M14K cells exposed to 50 
µM cisplatin showed caspase 3 cleavage within 48 h, which was not potentiated by BSO 
pretreatment. In M38K cells no apoptosis could be seen when assessed by caspase 3 cleavage after 
cisplatin exposure without or with BSO (Fig 5, V). Apoptosis was also assessed morphologically 
after the same exposures. Again cisplatin caused apoptosis in M14K cells but not in M38K cells, 
and apoptosis was not enhanced by BSO. Apoptotic index in M38K cells was very low (between 
2.4% in controls and 4.5% in cisplatin exposed BSO treated cells). 
 
The expression of P-glycoprotein and multidrug-resistance proteins 1 and 2 
(MRP1 and MRP2) in mesothelioma tissue biopsies (VI) 
 
Positive staining with the P-gp antibody was seen in 61 % of the mesothelioma tumor biopsies 
(n=36): 13 cases showed strong, five moderate, and four weak staining (Table 1, VI). The reactivity 
was mainly localized to the plasmamembrane. Epithelial and biphasic subtypes showed 
significantly more often strong immunoreactivity than did the sarcomatoid subtype (p=0.031). No 
positive staining was observed in non-malignant mesothelial cells. 
 
Positive immunoreactivity for MRP1 was seen in 58 % of the cases. The staining was both 
membrane-bound and cytoplasmic. Equal incidences of strong, moderate and weak 
immunoreactivity for MRP1 were seen. MRP1 reactivity was weaker in sarcomatoid than epithelial 
or biphasic mesotheliomas (p=0.034). No immunostaining was seen in samples of non-neoplastic 
mesothelium (Fig 1, VI).  
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MRP2 antibody detected non-specific nuclear immunostaining in addition to membrane-bound 
immunoreactivity, but only membrane-bound staining was considered significant. 33 % cases 
showed positive reactivity and the staining was usually weak. Significant association was detected 
between MRP2 and moderate or strong P-gp staining (p=0.021), but no association was found 
between MRP2 and MRP1 reactivity (p=0.41). Sarcomatoid mesotheliomas showed significantly 
more often negative MRP2 staining than epithelial and biphasic ones (p=0.024). Non-neoplastic 
mesothelium was not stained with MRP2 (Fig 1, VI). No significant association was found with 
patient survival and expression of any of the multidrug resistance proteins studied (p=0.135, p=0.09 
and p=0.88 for P-gp, MRP2 and MRP1, respectively). There was no association between these 
glycoproteins and tumor proliferation or apoptosis.  
 
We also looked for an association between expression of γGCS and that of MRP1 or MRP2. There 
was a significant correlation between γGCSh and MRP2 expression (p=0.048), whereas the 
correlation between γGCSl and MRP2 was not significant (p=0.35). No correlation was seen 
between MRP1 and γGCSh (p=0.67) or γGCSl (p=0.50), either. 
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Table 5. The expression of antioxidant enzymes and related mechanisms in mesothelial cell line 
(MeT5A), mesothelioma cell lines (M14K, M38K), lung adenocarcinoma cell line (A549), non-
malignant mesothelium and mesothelioma biopsies published by us or other laboratories.  The 
results have been assessed at the level of mRNA (Northern blot, NB), protein (Western blot, WB), 
immunohistochemistry (IH), and/or the specific activity (SA) or concentration (c), when available.  
Nd = not done. 
 
 
Antioxidant/
related 
mechanism 
Mesothelial 
cell line 
(MeT5A) 
Mesothelioma 
cell lines 
(M14K/ 
M38K) 
Lung 
adenocarcinoma 
cell line (A549) 
Non-
malignant 
mesothelium 
Mesothelioma 
tissue samples 
MnSOD + 
(NB,WB,IH,SA) 
+++ / +++ 
 (NB,WB,IH,SA) 
(+) (NB,WB,SA) neg (IH) +++ (IH) 
CuZnSOD + (NB,SA) ++ / ++ (NB,SA) nd nd nd 
Catalase + (NB,SA) ++/ +++ (NB,SA) +++ (SA) (neg, Kahlos, 
2001, IH) 
(+++, Kahlos, 2001, 
IH) 
GSH + (C) +/ +++ (C) +++ (C) nd nd 
GPx + (NB,SA) +(+)/ +(+) 
(NB,SA) 
nd nd nd 
GST + (WB,SA) ++/ +++ (WB,SA) + (SA) (++, Dejmek, 98, 
Segers, 96, IH) 
(++ (+), Dejmek, 
98, Segers, 96, IH) 
γGCSh + (WB) ++/ +++ (WB) +++ (WB) neg (IH) +++ (IH) 
γGCSl + (WB) +/ + (WB) + (WB) neg (IH) ++ (IH) 
MRP1 nd nd nd neg (IH) ++ (IH) 
MRP2 nd nd nd neg (IH) + (IH) 
P-gp nd nd nd neg (IH) ++ (IH) 
TRX nd (++/++, Kahlos, 
2001 NB,WB) 
(++, Soini, 2001, WB) (neg, Kahlos, 
2001, IH)  
(+++, Kahlos, 2001, 
IH) 
PRXI-VI (+, Kinnula, 
2001,WB) 
(+ - ++, Kinnula, 
2001, WB) 
nd (neg, Kinnula, 
2001, IH) 
(+-+++, Kinnula, 
2001, IH) 
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DISCUSSION 
 
MnSOD 
The role of MnSOD in cancer biology is controversial. In the literature, it has been stated 
repeatedly that MnSOD activity is diminished in cancer cells and regaining the activity will 
eventually decrease the state of malignancy (Oberley & Oberley). However, increased MnSOD 
activities have been documented in some cancer types, at least glioma (Cobbs et al., 1996), renal 
carcinoma (Oberley et al., 1994) colorectal cancers (Janssen et al., 1998) and thyroid malignancies 
(Nishida et al., 1993). In some of these cancers, increased MnSOD level has been linked with poor 
survival (Janssen et al., 1998; Ria et al., 2001).  
 
Many problems arise, however, when investigating the expression and role of MnSOD in cancer 
cells. The studies that have found increased MnSOD levels have been criticized by arguing that 
they have not included adequate controls or that they have not measured the specific activity of the 
enzyme (Oberley&Oberley). Then again studies evaluating the role of MnSOD in malignancy have 
often been done using gene transfection. The problem with transfection is that it does not mimic the 
actual in vivo situation, in which many antioxidants may be simultaneously induced. Transfection 
of the MnSOD cDNA alone results in accumulation of H2O2 and subsequent toxicity, which could 
lead to conclusions based on false assumptions. The balance of antioxidants is crucial in protecting 
the cell against various exogenous and endogenous oxidants (de Haan et al., 1996; Li et al., 2000; 
Thannickal & Fanburg, 2000). Conclusions have also been drawn from activity measurements 
directly in plasma samples from patients. Also tumor homogenates have been used to measure 
enzyme activities. Neither of these methods describes enzyme activity in a cancer cell. Tumor 
homogenates contain various cell types that are not always cancerous, like stroma. The problem 
with continuous cell lines is that the levels of AOEs usually decline in culture and selection of 
tumor cells also takes place during culture. The activity of an enzyme such as MnSOD in cultured 
cells may also be dependent on factors such as plating density, stage of cell growth, and 
constituents of the culture medium. It has to be noted that MnSOD is essential to living cells; 
knockout mice lacking the MnSOD gene are not viable (Li et al., 1995). Furthermore, transgenic 
animals expressing elevated lung MnSOD activity are more resistant to high oxygen tension than 
the control animals (Tsan, 2001). 
 
In this study, the level of MnSOD was found to be significantly higher in mesothelioma cells than 
in healthy mesothelium or non-malignant MeT5A mesothelial cells in vivo and in vitro. In addition 
to immunohistochemistry, in which tumor samples where compared with non-malignant 
mesothelium, MnSOD was further investigated using northern blot and western blot analysis, and 
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the specific activity of the enzyme was assessed. All these results confirm the hypothesis that 
MnSOD is overexpressed in human pleural mesothelioma.  
In the present study MeT5A was used as a model of a non-malignant cell line. It, however, does not 
represent a primary mesothelial cell line, as MeT5A has been transformed with SV40 and it has 
qualities of a reactive mesothelium. MeT5A cells are nevertheless non-cancerous with typical 
mesothelial characteristics. Due to the difficulties in obtaining healthy mesothelium for culture of 
human mesothelial cell, MeT5A cells have been widely used for this purpose. Since reactive 
mesothelium in vivo and also the cell clusters of MeT5A cells showed positive immunoreactivity 
(Kahlos et al., 2000a), MnSOD cannot be used in the differential diagnosis between reactive 
mesothelium and mesothelioma. The differential diagnosis between mesothelioma and 
adenocarcinoma in pleura is difficult. Further studies have shown that MnSOD is higher in primary 
malignant mesothelioma than in other tumors metastasized to pleura (Kahlos et al., 2000a). Thus 
MnSOD may play role in the differential diagnosis of mesothelioma. 
Studies on mesothelioma cell lines revealed that the cell line with the highest MnSOD activity 
(M38K) contained also the highest level of other antioxidants, like catalase and glutathione. M38K 
also turned out to be the most resistant of the mesothelioma cell lines. This supports the hypothesis 
that a simultaneous increase of many AOEs offers best protection. However, many mechanisms 
other than AOEs may also be overexpressed in this cell line, for example the apoptotic protein Bcl-
X (Soini et al., 1999), DNA repair mechanisms, or even the drug efflux pumps. 
It has been suggested that MnSOD cannot be induced in cancer cells (Wong & Goeddel, 1988). The 
present study, nevertheless, found that MnSOD protein and activity were increased by TNFα in 
both a mesothelioma cell line (M14K) and a pulmonary adenocarcinoma cell line (A549). This 
result is also in line with some other studies showing MnSOD induction in malignant cells at least 
by TNFα (Warner et al., 1996). In the present study MnSOD was induced more in A549 cells, in 
which the baseline MnSOD was low. Some of the cytotoxic drugs tended to increase MnSOD 
mRNA levels, but induction failed to reach significance. Induction in vivo is, however, possible. 
Other investigators (Akashi et al., 1996; Das et al., 1998) have shown that MnSOD mRNA was 
upregulated after anticancer drug treatment in cultured cells and that NF-κB is indeed induced by 
anticancer agents without TNFα involvement (Das & White, 1997). The induction in vivo is 
dependent on the drug concentration at the site of the tumor and time of exposure and these are 
difficult to mimic in cell cultures.  
Induced MnSOD level has been suggested to offer protection against oxidant stress such as 
radiotherapy (Wong & Goeddel, 1988). Pulmonary adenocarcinoma cells treated with TNFα had an 
elevated level of MnSOD and increased resistance to paraquat (Warner et al., 1996). Its role in 
anticancer drug resistance has however, remained unclear and controversial. In this study, MnSOD 
induction failed to offer extra protection against either oxidants or the anti-cancer drug epirubicin. 
If anything, the cells were more susceptible to oxidant injury. The effects of TNFα are, however, 
numerous and TNFα has been shown to induce the apoptotic pathways by activating NF-kB 
(Darnay & Aggarwal, 1997). There is evidence that higher MnSOD level offers protection against 
apoptosis by blocking the effects of TNFα and the same effect has been ascribed to γGCS that 
inhibits the activation of NF-kB and prevents the apoptotic cascade (Manna et al., 1998; Morales et 
al., 1997; Obrador et al., 1997). 
DISCUSSION 
 
 52 
Several studies on cell cultures and experimental models and MnSOD transfected cells have 
suggested that MnSOD reduces tumor cell proliferation (Oberley&Oberley). Kahlos et al reported 
that high MnSOD in mesothelioma correlates with decreased proliferation. However, there was no 
relationship between proliferation or spontaneous apoptosis and patient survival (Kahlos et al., 
2000b).  
Based on previous and the present results, MnSOD is elevated in mesothelioma and may possibly 
be used as an additional marker in the differential diagnosis of this disease. MnSOD induction does 
not protect malignant cells against oxidant and drug exposure, and besides MnSOD, H2O2 
scavenging AOEs may play an important role both in primary and acquired drug resistance. 
 
Catalase 
There are only a few studies on catalase in malignant tumors, and no major role has been proposed 
for it in anti-cancer drug resistance (Sinha & Mimnaugh, 1990; Tome et al., 2001). The present 
study showed that the mRNA and the specific activity of catalase were higher in the most resistant 
mesothelioma cell line compared to the non-malignant mesothelial cell line. In addition, a recent 
study confirmed the overexpression of catalase in mesothelioma. In that study a coordinate 
expression of catalase and MnSOD predicted a better survival of mesothelioma patients (Kahlos et 
al., 2001b).  However, in cultured mesothelioma cells, inactivation of catalase with ATZ did not 
have significant effect on the toxicity of epirubicin, although it increased the susceptibility to H2O2-
induced toxicity. This would imply a function for catalase during heavy oxidant exposure, which is 
in line with its physiological role (Halliwell&Gutteridge). On the other hand, ATZ does not 
completely inactivate catalase, so these studies may underestimate its role. Besides MnSOD and 
CAT, high oxidant resistance of mesothelioma may thus involve a simultaneous induction of many 
other antioxidant mechanisms most importantly the glutathione system.  
 
Glutathione and GSH-related enzymes 
The level of glutathione has often been linked with anti-cancer drug resistance (O'Brien & Tew, 
1996; Tew, 1994; Zhang et al., 1998). Glutathione can confer resistance to cytotoxic drugs that 
cause ROS generation through the classical antioxidant pathway, the glutathione redox cycle. It is 
also irreversibly consumed in detoxification reactions catalyzed by GSTs. Also some of the 
plasmamembrane drug efflux pumps, mainly MRP1 and MRP2, are dependent on glutathione 
(Borst et al., 2000). Resistance to apoptosis has been suggested to be redox-regulated as well 
(Manna et al., 1998; Susin et al., 1998). Therefore, the synthesis and maintenance of the 
intracellular GSH level and the GSH:GSSG ratio are relevant for optimal defense against cytotoxic 
drugs.  
 
M38K, the most resistant mesothelioma cell line, contained not only the highest level of MnSOD 
and catalase, but also of glutathione, glutathione peroxidase, glutathione S-transferase and γGCSh. 
Depletion of intracellular glutathione resulted in reversal of the resistance to epirubicin and 
cisplatin. Additional studies with the adenocarcinoma cell line A549 also emphasized the 
importance of the glutathione system both in the oxidant and drug resistance. A549 had a higher 
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level of glutathione and γGCS compared to M14K. Inhibition of γGCS with BSO also enhanced the 
oxidant and drug (cisplatin) sensitivity of these cells significantly. A549 cell line is a resistant cell 
line to oxidants and oxidant producing drugs, but in these cells the MnSOD level was very low 
whereas GSH content was high. In light of these results, glutathione depletion with BSO could 
possibly have therapeutic implications in lung cancer and mesothelioma. One way of reversing the 
resistance could be injection of BSO intrapleurarly to avoid the systematic problems of glutathione 
depletion. In fact, phase I trials have been conducted with BSO and melphalan, and the continuous-
infusion BSO was relatively nontoxic and resulted in depletion of tumor glutathione (Bailey et al., 
1997). 
 
The capacity to synthesize GSH is essential in protection and detoxification reactions of non-
malignant and malignant cells. In addition to cysteine availability, the expression and activity of 
γGCS is of major importance in maintaining adequate levels of GSH. Most articles regarding γGCS 
have been studies on γGCSh and its regulation, lately some studies have been published also on the 
light subunit (Galloway et al., 1997; Shi et al., 1994; Tipnis et al., 1999; Zhang et al., 1998). Both 
subunits of γGCS have been connected with resistance against melphalan, doxorubicin and cisplatin 
(Iida et al., 1999). No studies have, however, been done with the actual expression and distribution 
of the enzyme subunits in malignant tumors. There is a recent microarray study comparing a 
mesothelioma cell line with a non-malignant mesothelioma cell line showing increased expression 
of γGCS in the malignant cell (Rihn et al., 2000). Yet only mRNA, not protein, was detected from 
these cells. 
 
In the present study all mesothelioma cell lines expressed both subunits of γGCS. The highest level 
of γGCSh, which is responsible for the catalytic activity, was found, not surprisingly, in the M38K 
cells. In immunohistochemistry most mesotheliomas expressed both subunits of γGCS. Healthy 
mesothelium was negative, but by immunohistochemistry the presence of small amounts of the 
enzyme in healthy tissue cannot be excluded. No correlation between patient survival and γGCS 
expression was observed. On the other hand, the overall prognosis of mesothelioma is poor and the 
survival time is not always reliable as the time of diagnostic biopsy within the time span of the 
disease varies uncontrollably between patients. Results from a recent immunohistochemical study 
with lung cancer biopsies also showed that both subunits of γGCS are abundantly expressed in lung 
cancer cells (Soini et al., 2001b). In these samples a positive correlation was found between high 
apoptotic tendency and low γGCS expression. These results are in line with the previous report that 
γGCS is antiapoptotic as it changes the redox-state of the cell possibly by inhibiting the pro-
apoptotic signals caused by e.g. TNFα (Manna et al., 1998). This same result was not achieved 
with the mesothelioma biopsies. In the present study BSO pretreatment of mesothelioma cell lines 
that was followed by cisplatin exposure did not enhance apoptosis in M38K cells, indicating strong 
resistance towards apoptosis but also other mechanisms than the redox state in controlling the 
apoptotic pathway.  
 
GST-π has been reported to be overexpressed in neoplastic tissues (O'Brien & Tew, 1996). Also the 
relationship between the overexpression of GSTs and the sensitivity of tumor cells has been 
documented (Hao et al., 1994, reviewed by Zhang et al., 1998). The present study found a higher 
DISCUSSION 
 
 54 
expression of GST-π in the M38K cell line than the more sensitive mesothelioma cell line and the 
non-malignant cell line. In the adenocarcinoma cell line the activity of total GST was considerably 
lower compared to the mesothelioma cell lines. On the other hand, A549 cells were more resistant 
to oxidants and cytotoxic drugs and had a significantly higher GSH-level than mesothelioma cells. 
These results are in line with others showing that GSH and its re-synthesis capacity explain the 
resistance of A549 cells to cytotoxic drugs (al-Kabban et al., 1990), cadmium (Hatcher et al., 1995) 
and oxidants (Arsalane et al., 1997; Rahman et al., 2001). On the other hand, there are studies 
showing that lung cancer cell lines can express several GSTs and GPx without a GSH increase 
(Hao et al., 1994). Multiple detoxification mechanisms may thus be involved and non-enzymatic 
detoxification by glutathione conjugation may take place as well. The resistance mechanisms must 
also differ between different drugs since their way of killing the cancer cells is diverse. 
Anthracyclins that cause ROS formation are possibly detoxified in part by AOEs. On the other 
hand, cisplatin may not cause oxidative stress and thus it may be conjugated to GSH and exported 
from the cell; the role of MnSOD and other antioxidants in cisplatin resistance may therefore be 
minimal.  
The induction of the salvage enzyme γGT has been reported during the development of drug 
resistance. In a study analyzing 451 human cancers, all 10 mesothelioma samples were negative for 
γGT immunoreactivity (Hanigan et al., 1999). This suggests that intracellular glutathione levels are 
maintained with de novo synthesis probably by γGCS. 
To conclude, the present study emphasized the importance of GSH-related mechanisms in the 
intrinsic resistance of mesothelioma, and these findings were supported by studies conducted with 
lung adenocarcinoma cells. High expression of γGCS is of major importance both in the 
detoxification pathway and the antioxidant function of these cells.  
 
P-gp and MRP1&2 
The plasmamembrane pumps have been extensively studied, and the emphasis has been on P-gp 
(Pastan & Gottesman, 1987). One study on cultured mesothelioma cell lines suggested that the 
resistance to vindesin and doxorubicin is P-gp dependent. In that study, however, the baseline 
expression of P-gp was almost undetectable, and the expression increased when exposing the cells 
continuously to the cytotoxic drugs (Licht et al., 1991; Licht et al., 1995) Therefore, P-gp is not 
likely to account for the primary resistance of the tumor. In an immunohistochemical study on 33 
mesothelioma tumor biopsies, P-gp was expressed in the majority of tumors (Ramael et al., 1992). 
In another study on the expression of P-gp, MRP1 and γGCS in five mesothelioma cell lines the 
conclusion was that MRP1 and γGCS may be co-ordinately overexpressed in doxorubicin-resistant 
cells (Ogretmen et al., 1998).  
The present study found the expression level of P-gp to line up with findings from other tumors, 
such as kidney, colon and liver (Duensing & Slate, 1994; Sinicrope et al., 1992; Soini et al., 1996). 
MRP1 was expressed in the majority of the biopsies, which is in agreement with other tumors such 
as colon and gastric cancers (Endo et al., 1996; Fukushima et al., 1999). MRP2 was expressed in 
only 33% of mesotheliomas, and the staining was usually weak. It has been detected in unselected 
lung, gastric and colorectal tumor cell lines (Kool et al., 1997; Taniguchi et al., 1996). None of 
DISCUSSION 
 
 55 
these proteins correlated with patient survival so the expression of these efflux proteins cannot be 
used as a prognostic factor. A recent study has suggested that even a low expression of these 
transport proteins may cause clinical drug resistance, as the maximum dose of a cytotoxic drug 
tolerated by the patient is often barely sufficient to kill a useful percentage of the tumor cells (Allen 
et al., 2000). Therefore relatively small increases in the drug resistance in tumor cells are sufficient 
to make the drug clinically ineffective. Our results show that these transporters cannot be used for 
the assessment of primary resistance, as most patients did not receive chemotherapy and the efflux 
pumps are not known to cause proliferation of the malignant cells or progression of the disease. In 
agreement with this neither tumor proliferation nor apoptosis showed any association with the 
expression of the multidrug resistance proteins.  
γGCS expression correlated with MRP2, but not with MRP1. A connection has been made with 
γGCS and MRP1 in a number of studies (Ishikawa et al., 1996; Kuo et al., 1996) but no 
corresponding studies on MRP2 are available. MRP2 has not, however, been studied as much and 
even its expression in different malignancies is largely unknown. Cisplatin has been shown to cause 
upregulation of MRP2, and MRP2 to cause resistance against cisplatin (Borst et al., 2000; Konig et 
al., 1999). Most of our patients had not received chemotherapy so the immunoreactivity of MRP2 
describes primary, not cisplatin induced, expression of the protein. (Ishikawa et al., 1996. It 
remains to be investigated whether this correlation has any true significance in resistance of 
mesothelioma, as the expression of MRP2 is weak altogether and present only in 33% of the 
biopsies. In contrast of trying to find significant associations with patient survival, the expression of 
these mechanisms might be considered as tumor characteristics that can be used when trying to 
understand the natural course of this malignancy. In fact the actual role of these efflux proteins in 
the clinical primary resistance of any malignant tumor is far from clear. For example, new members 
to the MRP family have been discovered (Bera et al., 2001) and their contribution to clinical drug 
resistance has not yet been studied.  
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CONCLUSIONS 
Malignant pleural mesothelioma shows a simultaneous high expression of several antioxidant 
enzymes and related proteins. These mechanisms may play an important role in the overall poor 
prognosis, and in the drug resistance of this disease. The following conclusions can be drawn from 
the present study: 
 
1. The level of MnSOD is significantly higher in malignant mesothelioma cells than in non-
malignant mesothelial cells both in vitro and in vivo. High MnSOD can be detected at the level 
of mRNA, immunoreactive protein and specific activity. 
 
2. MnSOD in mesothelioma cells can be induced by TNFα but not by the cytotoxic drugs. 
Induction of MnSOD, however, does not provide any protection against repeated oxidant or 
drug exposures. Additional studies with lung adenocarcinoma cells further suggest the 
importance of high glutathione content in the oxidant and drug resistance of these cells.  
 
3. The resistance of mesothelioma cells in vitro is partly associated with glutathione and 
glutathione S-transferase whereas the significance of catalase is limited only to heavy oxidant 
exposure. 
 
4. In addition to MnSOD, γGCS, the rate-limiting enzyme in glutathione synthesis, is expressed at 
high quantities in most mesotheliomas. γGCS may play role in the overall primary drug 
resistance of malignant lung cells, since treatment of mesothelioma and lung adenocarcinoma 
cells with BSO, to inhibit γGCS, significantly potentiates drug-induced cytotoxicity. 
 
5. Variable expression of P-gp, MRP1 and MRP2 can be detected in malignant mesothelioma, 
suggesting that the primary resistance of mesothelioma is not solely dependent on their 
expression or function. As tumor growth, apoptosis or patient survival do not associate with 
these membrane glycoproteins, they cannot be used as a prognostic factor in mesothelioma.    
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